Abelson JL, Glitz D, Cameron OG et al (1991) Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 48:157–162
PubMedCrossRefAbelson JL, Khan S, Liberzon I, Young EA (2007) HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety 24:66–76
PubMedCrossRefAcarturk C, Smit F, de Graaf R et al (2009) Incidence of social phobia and identification of its risk indicators: a model for prevention. Acta Psychiatr Scand 119:62–70
PubMedCrossRefAderka IM (2009) Factors affecting treatment efficacy in social phobia: the use of video feedback and individual vs. group formats. J Anxiety Disord 23:12–17
PubMedCrossRefAgyropoulos SV, Nutt DJ (2003) Neurochemical aspects of anxiety. In: Nutt DJ, Ballenger JC (Hrsg) Anxiety disorders. Blackwell Science, Malden/Oxford, S 183–199
Alamy S, Wei Zhang, Varia I et al (2008) Escitalopram in specific phobia: results of a placebo-controlled pilot trial. J Psychopharmacol 22:157–161
PubMedCrossRefAllen LB, Barlow DH (2006) Treatment of panic disorder: outcomes and basic processes. In: Rothbaum BO (Hrsg) Pathological anxiety: emotional processing in etiology and treatment. Guilford, New York, S 166–180
Allgulander C (2010) Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry 23:37–42
PubMedCrossRefAllgulander C, Hackett D, Salinas E (2001) Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179:15–22
PubMedCrossRefAllgulander C, Dahl AA, Austin C et al (2004a) Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161:1642–1649
PubMedCrossRefAllgulander C, Mangano R, Zhang J et al (2004b) Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19:387–396
PubMedCrossRefAllgulander C, Florea I, Huusom AK (2006) Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:495–505
PubMedCrossRefAllgulander C, Hartford J, Russell J et al (2007) Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin 23:1245–1252
PubMedCrossRefAllgulander C, Nutt D, Detke M et al (2008) A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol 22:417–424
PubMedCrossRefAlnas R (2001) Social phobia: research and clinical practice. Nord J Psychiatry 55:419–425
CrossRefAlsene K, Deckert J, Sand P, de Wit H (2003) Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28(9):1694–1702
PubMedCrossRefAlvarez RP, Chen G, Bodurka J, Kaplan R, Grillon C (2011) Phasic and sustained fear in humans elicits distinct patterns of brain activity. Neuroimage 55:389–400
PubMedCrossRefAmiel JM, Mathew SJ (2007) Glutamate and anxiety disorders. Curr Psychiatry Rep 9:278–283
PubMedCrossRefArch JJ, Craske MG (2009) First-line treatment: a critical appraisal of cognitive behavioral therapy developments and alternatives. Psychiatr Clin North Am 32:525–547
PubMedCrossRefArnsten AFT (2009) Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 10:410–422
PubMedPubMedCentralCrossRefArntz A, Rauner M, van den Hout M (1995) „If I feel anxious, there must be danger“: ex-consequentia reasoning in inferring danger in anxiety disorders. Behav Res Ther 33:917–925
PubMedCrossRefAsmundson GJ, Katz J (2009) Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress Anxiety 26:888–901
PubMedCrossRefAustin DW, Richards JC (2001) The catastrophic misinterpretation model of panic disorder. Behav Res Ther 39:1277–1291
PubMedCrossRefAyala ES, Meuret AE, Ritz T (2009) Treatments for blood-injury-injection phobia: a critical review of current evidence. J Psychiatr Res 43:1235–1242
PubMedCrossRefBakish D, Huusom AKT, Legault M (2006) Escitalopram prevents relapse in generalized anxiety disorder: an analysis of date from Canadian patients participating in a multinational clinical study. Int J Neuropsychopharmacol 9:185–186
Baldwin DS, Polkinghorn C (2005) Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 8:293–302
PubMedCrossRefBaldwin DS, Huusom AK, Maehlum E (2006) Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 189:264–272
PubMedCrossRefBaldwin DS, Loft H, Florea I (2012) Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol 27:197–207
PubMedCrossRefBalint M (1970) Therapeutische Aspekte der Regression: Die Theorie der Grundstörung. Klett-Cott, Stuttgart
Ball SG, Kuhn A, Wall D et al (2005) Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 66:94–99
PubMedCrossRefBandelow B (1995) The assessment of efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 10:73–82
PubMedCrossRefBandelow B, Baldwin DS (2009) Pharmacotherapy for panic disorder. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 399–416
Bandelow B, Seidler-Brandler U, Becker A et al (2007) Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 8:175–187
PubMedCrossRefBandelow B, Zohar J, Hollander E et al (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 9:248–312
PubMedCrossRefBandelow B, Chouinard G, Bobes J et al (2009) Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 20:1–16
Bandelow B, Chouinard G, Bobes J et al (2010) Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13:305–320
PubMedCrossRefBandelow B, Wiltink J, Alpers GW, Benecke C, Deckert J, Eckhardt-Henn A, Ehrig C, Engel E, Falkai P, Geiser F, Gerlach AL, Harfst T, Hau S, Joraschky P, Kellner M, Kölner V, Kopp I, Langs G, Lichte T, Liebeck H, Matzat J, Reitt M, Rüddel HP, Rudolf S, Schick G, Schweiger U, Simon R, Springer A, Staats H, Ströhle A, Ströhm W, Waldherr B, Watzke B, Wedekind D, Zottl C, Zwanzger P, Beutel M (2013) Deutsche S3-Leitlinie zur Behandlung von Angststörungen
Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D (2015) Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 30(4):183–92
PubMedCrossRefBaraldi M, Avallone R, Corsi L et al (2009) Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy. Metab Brain Dis 24:81–93
PubMedCrossRefBarlow DH (2000) Unraveling the mysteries of anxiety and its disorders from the perspective of emotion theory. Am Psychol 55:1245–1263
CrossRefBarlow DH (2002) Anxiety and its disorders: the nature and treatment of anxiety and panic, 2. Aufl. Guilford, New York
Barlow DH, Blanchard EB, Vermilyea JA et al (1986) Generalized anxiety and generalized anxiety disorder: description and reconceptualization. Am J Psychiatry 143:40–44
PubMedCrossRefBarlow DH, Gorman JM, Shear MK, Woods SW (2000) Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 283(19):2529–36
PubMedCrossRefBarrera TL, Norton PJ (2009) Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord 23:1089–1090
CrossRefBatelaan NM, de Graaf R, Penninx BW, van Balkom AJ, Vollebergh WA, Beekman AT (2010) The 2-year prognosis of panic episodes in the general population. Psychol Med 40(1):147–157
PubMedCrossRefBatelaan NM, Spijker J, de Graaf R, Culipers P (2012) Mixed anxiety depression should not be included in DSM-5. J Nerv Ment Dis 200(6):495–498
PubMedCrossRefBeck AT (2005) Cognitive therapy: a 40-year retrospective. Arch Gen Psychiatry 62:953–959
PubMedCrossRefBeck AT, Emery G, Greenberg RL (1985) Anxiety disorders and phobias: a cognitive perspective. Basic Books, New York
Beck AT, Epstein N, Brown G et al (1988) An inventory for measuring clinical anxiety. J Consult Clin Psychol 52:1090–1097
Becker ES, Rinck M, Türke V et al (2007) Epidemiology of specific phobia subtypes: findings from the Dresden Mental Health Study. Eur Psychiatry 22:69–74
PubMedCrossRefBeesdo K, Knappe S, Pine DS (2009a) Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin N Am 32:483–524
CrossRefBeesdo K, Hartford J, Russell J et al (2009b) The short- and long-term effect of duloxetine on painful physical symptoms in patients with generalized anxiety disorder: results from three clinical trials. J Anxiety Disord 23:1064–1071
PubMedCrossRefBehar E, DiMarco ID, Hekler EB et al (2009) Current theoretical models of generalized anxiety disorder (GAD): conceptual review and treatment implications. J Anxiety Disord 23:1011–1023
PubMedCrossRefBeitman BD, Basha I, Flaker G (1987) Non-fearful panic disorder: panic attacks without fear. Behav Res Ther 25:487–492
PubMedCrossRefBekker MH, van Mens-Verhulst J (2007) Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend Med 4:178–193
CrossRefBelzer KD, McKee MB, Liebowitz MR (2005) Social anxiety disorder: current perspectives on diagnosis and treatment. Prim Psychiatry 12:35–48
Bentz D, Michael T, de Quervain DJ, Wilhelm FH (2010) Enhancing exposure therapy for anxiety disorders with glucocorticoids: from basic mechanisms of emotional learning to clinical applications. J Anxiety Disord 24:223–230
PubMedCrossRefBerger T, Hohl E, Caspar F (2009) Internet-based treatment for social phobia: a randomized controlled trial. J Clin Psychol 65:1021–1035
PubMedCrossRefBerman NC, Wheaton MG, McGrath P, Abramowitz JS (2010) Predicting anxiety: the role of experiential avoidance and anxiety sensitivity. J Anxiety Disord 24:109–113
PubMedCrossRefBidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV (2012) Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol 22:847–857
PubMedCrossRefBiederman J, Petty CR, Faraone SV et al (2006) Antecedents to panic disorder in nonreferred adults. J Clin Psychiatry 67:1179–1186
PubMedCrossRefBielski RJ, Bose A, Chang C (2005) A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 17:65–69
PubMedCrossRefBirbaumer N, Grodd W, Diedrich O et al (1998) fMRI reveals amygdalae activation to human faces in social phobics. Neuroreport 9:1223–1226
PubMedCrossRefBirn RM, Shackman AJ, Oler JA, Williams LE, McFarlin DR, Rogers GM, Shelton SE, Alexander AL, Pine DS, Slattery MJ, Davidson RJ, Fox AS, Kalin NH (2014) Evolutionarily conserved prefrontal-amygdalar dysfunction in early-life anxiety. Mol Psychiatry 19:915–922
PubMedPubMedCentralCrossRefBlair K, Geraci M, Devido J (2008) Neural response to self- and other referential praise and criticism in generalized social phobia. Arch Gen Psychiatry 65:1176–1184
PubMedPubMedCentralCrossRefBlanco C, Schneier FR, Vesga-López, Liebowitz MR (2009) Pharmacotherapy for social anxiety disorder. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 471–499
Blomhoff S, Haug TT, Hellstrom K et al (2001) Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179:23–30
PubMedCrossRefBlum K, Braverman ER, Wu S et al (1997) Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Mol Psychiatry 2:239–246
PubMedCrossRefBobes Garcia J, Montgomery S, Baldinetti F et al (2007) Pregabalin for the treatment of generalized anxiety disorder (GAD): efficacy and safety in elderly patients. Eur Psychiatry 22:280
CrossRefBolton JM, Cox BM, Afifi TO et al (2008) Anxiety disorders and risk for suicide attempts: findings from the Baltimore Epidemiologic Catchment area follow-up study. Depress Anxiety 25:477–481
PubMedCrossRefBond M, Perry JC (2004) Long-term changes in defense styles with psychodynamic psychotherapy for depressive, anxiety, and personality disorders. Am J Psychiatry 161:1665–1671
PubMedCrossRefBontempo A, Panza KE, Bloch MH (2012)
d-Cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. J Clin Psychiatry 73:533–537
PubMedPubMedCentralCrossRefBorge FM, Hoffart A, Sexton H et al (2008) Residential cognitive therapy versus residential interpersonal therapy for social phobia: a randomized clinical trial. J Anxiety Disord 22:991–1010
PubMedCrossRefBorkovec ID (1994) The nature, functions and origins of worry. In: Davey GCL, Tallis F (Hrsg) Worrying: perspectives on theory, assessment, and treatment. Wiley, New York, S 5–23
Borkovec TD (2006) Applied relaxation and cognitive therapy for pathological worry and generalized anxiety disorder. In: Davey GCL, Wells A (Hrsg) Worry in its psychological disorders: theory, assessment and treatment. Wiley, Chichester, S 273–287
CrossRefBoschen MJ (2012) Pregabalin: dose-response relationship in generalized anxiety disorder. Pharmacopsychiatry 45:51–56
PubMedCrossRefBouton ME, Mineka S, Barlow DH (2001) A modern learning theory perspective on the etiology of panic disorder. Psychol Rev 108:4–32
PubMedCrossRefBouwer C, Stein DJ (1997) Association of panic disorder with a history of traumatic suffocation. Am J Psychiatry 154:1566–1570
PubMedCrossRefBowlby J (1976) Trennung. Psychische Schäden als Folge der Trennung von Mutter und Kind. Kindler, München
Bracha HS (2004) Freeze, flight, fight, fright, faint: adaptationist perspectives on the acute stress response spectrum. CNS Spectr 9:679–685
PubMedCrossRefBracha HS (2006) Human brain evolution and the „neuroevolutionary time-depth principle“: implications for the reclassification of fear-circuitry-related traits in DSM-V and for studying resilience to warzone-related posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:827–853
PubMedCrossRefBradwejn J, Ahokas A, Stein DJ et al (2005) Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 187:352–359
PubMedCrossRefBrandt T (1996) Phobic postural vertigo. Neurology 46:1515–1519
PubMedCrossRefBrawman-Mintzer O, Lydiard RB (1997) Biological basis of generalized anxiety disorder. J Clin Psychiatry 58(Suppl 3):16–25
PubMedBrawman-Mintzer O, Lydiard RB, Emmanuel N, Payeur R, Johnson M, Roberts J, Jarrell MP, Ballenger JC (1993) Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 150(8):1216–8
PubMedCrossRefBrawman-Mintzer O, Knapp RG, Nietert PJ (2005) Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 66:1321–1325
PubMedCrossRefBrawman-Mintzer O, Knapp RG, Rynn M et al (2006a) Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67:874–881
Brawman-Mintzer O, Nietert PJ, Rynn MA et al (2006b) Quetiapine monotherapy in patients with GAD. Paper presented at the annual meeting of the American Psychiatric Association, Toronto
Briggs AC, Stretch DD, Brandon S (1993) Subtyping of panic disorder by symptom profile. Br J Psychiatry 163:201–209
PubMedCrossRefBritton JC, Rauch SL (2009) Neuroanatomy and neuroimaging of anxiety disorders. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 97–110
Bruce TJ, Speigel DA, Gregg SF, Nuzzarello A (1995) Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. Am J Psychiatry 152:1156–1160
PubMedCrossRefBruce SE, Machan JT, Dyck I, Keller MB (2001) Infrequency of „pure“ GAD: impact of psychiatric comorbidity on clinical course. Depress Anxiety 14:219–225
PubMedCrossRefBruce SE, Yonkers KA, Otto MW et al (2005) Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 162:1179–1187
PubMedPubMedCentralCrossRefBuller R, Benkert O, Maier W (1986) Clinical subtypes in panic disorder: their descriptive and prospective validity. J Affect Disord 11:105–114
PubMedCrossRefBuller R, Maier W, Benkert O (1988) Das Paniksyndrom: Symptome, Verlauf, Prädiktoren. In: Hippius H, Ackenheil M, Engel RR (Hrsg) Angst – Leitsymptom psychiatrischer Erkrankungen. Springer, Berlin/Heidelberg/New York/Tokio, S 60–67
Busch F, Milrod B (2004) Nature and treatment of panic disorder. In: Panksepp J (Hrsg) Textbook of biological psychiatry. Wiley, Hoboken, S 345–366
Busch F, Cooper A, Klerman GL et al (1991) Neurophysiological, cognitive-behavioral, and psychoanalytic approaches to panic disorder: toward an integration. Psychoanal Inq 11:316–332
CrossRefBusch F, Milrod B, Cooper A, Shapiro T (1996) Psychodynamic approaches to panic disorder. J Psychother Pract Res 5:73–83
Busch FN, Milrod BL, Shear MK (2009) Psychodynamic concepts of anxiety. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 117–128
Butler G, Fennell M, Robson P, Gelder M (1991) Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 59:167–175
PubMedCrossRefBystritsky A (2006) Treatment-resistant anxiety disorders. Mol Psychiatry 11(9):805–814
PubMedCrossRefCameron OG, Thyer BA, Nesse RM et al (1986) Symptom profiles of patients with DSM-III anxiety disorders. Am J Psychiatry 143:1132–1137
PubMedCrossRefCammin-Nowak S, Helbig-Lang S, Lang T, Gloster AT, Fehm L, Gerlach AL, Ströhle A, Deckert J, Kircher T, Hamm AO, Alpers GW, Arolt V, Wittchen HU (2013) Specificity of homework compliance effects on treatment outcome in CBT: evidence from a controlled trial on panic disorder and agoraphobia. J Clin Psychol 69(6):616–629
PubMedCrossRefCanli T, Lesch KP (2007) Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci 10:1103–1109
PubMedCrossRefCanli T, Ferri J, Duman EA (2009) Genetics of emotion regulation. Neuroscience 164:43–54
PubMedCrossRefCarter CS, Braver TS, Barch DM et al (1998) Anterior cingulate cortex, error detection, and the online monitoring of performance. Science 280(5364):747–749
PubMedCrossRefCharney DS (2003) Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand 108(Suppl 417):38–50
CrossRefCharney DS, Drevets WD (2002) Neurobiological basis of anxiety disorders. In: Davis KL, Charney DS, Coyle JT et al (Hrsg) Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Baltimore, S 901–930
Charney DS, Heninger GR (1986) Abnormal regulation of noradrenergic function in panic disorders: effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 43:1042–1054
PubMedCrossRefCharney DS, Woods SW, Heninger GR (1989) Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res 27:173–182
PubMedCrossRefChessick CA, Allen MH, Thase M et al (2006) Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev (3):CD006115
Choy Y, Fer AJ, Lipsitz JD (2007) Treatment of specific phobia in adults. Clin Psychol Rev 27:266–286
PubMedCrossRefChristmas D, Hood S, Nutt D (2008) Potential novel anxiolytic drugs. Curr Pharm Des 14:3534–3546
PubMedCrossRefCisler JM, Olatunji BO, Lohr JM (2009) Disgust, fear, and the anxiety disorders: a critical review. Clin Psychol Rev 29:34–46
PubMedCrossRefClark DG, Agras WS (1991) The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 148:598–605
PubMedCrossRefClark DM, McManus F (2002) Information processing in social phobia. Biol Psychiatry 51:92–100
PubMedCrossRefClark DM, Wells A (1995) A cognitive model of social phobia. In: Heimberg RG, Liebowitz MR, Hope DA et al (Hrsg) Social phobia: assessment and treatment. Guilford, New York, S 69–93
Clark DM, Salkovskis PM, Hackmann A et al (1994) A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 164:759–769
PubMedCrossRefClark DM, Salkovskis PM, Hackmann A et al (1999) Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol 67:583–589
PubMedCrossRefClark DM, Ehlers A, McManus F et al (2003) Cognitive therapy versus fluoxetine in generalized social phobia: a randomized, placebo-controlled trial. J Consult Clin Psychol 71:1058–1067
PubMedCrossRefClark DM, Ehlers A, Hackman A et al (2006) Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial. J Consult Clin Psychol 74:568–578
PubMedCrossRefCloitre M, Shear MK (1995) Psychodynamic perspectives. In: Stein MB (Hrsg) Social phobia: clinical and research perspectives. American Psychiatric Press, Washington, DC, S 163–187
Cloninger CR (1987) A systematic method für clinical description and classification of personality variants. Arch Gen Psychiatry 44:579–588
CrossRefCloos JM, Ferreira V (2009) Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 22:90–95
PubMedCrossRefCollegium Internationale Psychiatriae Scalarum (Hrsg) (1996) Internationale Skalen für Psychiatrie, 4. Aufl. Beltz, Göttingen
Condren RM, Lucey JV, Thakore JH (2003) A preliminary study of baclofen-induced growth hormone release in generalised social phobia. Hum Psychopharmacol 18:125–130
PubMedCrossRefCortese BM, Phan KL (2005) The role of glutamate in anxiety and related disorders. CNS Spectr 10:820–830
PubMedCrossRefCoupland NJ, Bell C, Potokar JP, Dorkins E, Nutt DJ (2000) Flumazenil in social phobia. Depress Anxiety 11:27–30
PubMedCrossRefCowley DS, Roy-Byrne PP, Hommer D et al (1991) Benzodiazepine sensitivity in anxiety disorders. Biol Psychiatry 29:57 A
Craig BAD (2009) How do you feel – now? The anterior insula and human awareness. Nat Rev Neurosci 10:59–70
PubMedCrossRefCraske MG, Barlow DH (2007) Mastery of your anxiety and panic (therapist guide), 4. Aufl. Oxford University Press, Oxford
Craske MG, Waters AM (2005) Panic disorder, phobias, and generalized anxiety disorder. Annu Rev Clin Psychol 1:197–225
PubMedCrossRefCraske MG, Roy-Byrne PP, Stein MB et al (2009b) Treatment for anxiety disorders: efficacy to effectiveness to implementation. Behav Res Ther 47:931–937
PubMedPubMedCentralCrossRefCrestani F, Lorenz M, Baer K (1999) Decreased GABA-A receptor clustering results in enhanced anxiety and bias for threat cues. Nat Neurosci 2:833–839
PubMedCrossRefCrippa JA, Filho AS, Freitas MC, Zuardi AW (2007) Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol 27:310
PubMedCrossRefCrits-Christoph P, Crits-Christoph K, Wolf-Palacio D et al (1995) Brief supportive-expressive psychodynamic therapy for generalized anxiety disorder. In: Barber JP, Crits-Christoph P (Hrsg) Dynamic therapies for psychiatric disorders (axis I). Basic Books, New York, S 43–83
Crits-Christoph P, Connolly MB, Azrian K et al (1996) Psychodynamic-interpersonal treatment of generalized anxiety disorder. Psychotherapy 33:418–430
CrossRefCrum RM, Pratt LA (2001) Risk of heavy drinking and alcohol use disorders in social phobia: a prospective analysis. Am J Psychiatry 158:1693–1700
PubMedCrossRefCulpepper L (2009) Generalized anxiety disorder and medical illness. J Clin Psychiatry 70(Suppl 2):20–24
PubMedCrossRefCurtis GC, Magee WJ, Eaton WW, Wittchen HU (1998) Specific fears and phobias: epidemiology and classification. Br J Psychiatry 173:212–217
PubMedCrossRefCuthbert B (2010) Early prevention in childhood anxiety disorders. Am J Psychiatry 167:1428–1430
PubMedCrossRefDalton KM, Kalin NH, Grist TM, Davidson RJ (2005) Neural-cardiac coupling in threat evoked anxiety. J Cogn Neurosci 17:696–980
CrossRefDarcis T, Ferreri M, Natens J et al (1995) A multicenter double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. Hum Psychopharmacol 10:181–187
CrossRefDavidson JR (2009) First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry 2:25–31
CrossRefDavidson JRT, Hughes DC, George LK et al (1993a) The epidemiology of social phobia: findings from the Duke epidemiological catchment area study. Psychol Med 23:709–718
PubMedCrossRefDavidson JRT, Potts NLS, Richichi EA et al (1993b) Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13:423–428
PubMedCrossRefDavidson JR, DuPont RL, Hedges D et al (1999) Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528–535
PubMedCrossRefDavidson JR, Bose A, Korotzer A, Zheng H (2004) Escitalopram in the generalized anxiety disorder: double-blind, placebo controlled flexible-dose study. Depress Anxiety 19:234–240
PubMedCrossRefDavidson JR, Bose A, Wang Q (2005) Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 66:1441–1446
PubMedCrossRefDavidson J, Allgulander C, Pollack MH et al (2008a) Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol 23:519–526
PubMedCrossRefDavis M (1998) Are different parts of the extended amygdala involved in fear versus anxiety. Biol Psychiatry 44:1239–1247
PubMedCrossRefDavis M, Myers KM, Chhatwal J, Ressler KJ (2006) Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy. NeuroRx 3:82–96
PubMedPubMedCentralCrossRefDavis M, Walker DL, Miles L, Grillon C (2010) Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 35:105–135
PubMedCrossRefDe Masi F (2004) The psychodynamic of panic attacks: a useful integration of psychoanalysis and neuroscience. Int J Psychoanal 85:311–336
PubMedCrossRefDeci PA, Lydiard B, Santos AB (1992) Oral contraceptives and panic disorder. J Clin Psychiatry 53:163–165
PubMedDembert ML, Dinneen MP, Opsahl MS (1994) Estrogen-induced panic disorder. Am J Psychiatry 151:1246
PubMedDemertzis KH, Craske MG (2005) Cognitive-behavioral therapy for anxiety disorders in primary care. Prim Psychiatry 12:52–58
Demyttenaere K (2014) Agomelatine in treating generalized anxiety disorder. Expert Opin Investig Drugs 23:857–864
PubMedCrossRefDenys D, De Geus F (2005) Predictors of pharmacotherapy response in anxiety disorders. Curr Psychiatry Rep 7:252–257
PubMedCrossRefDerogatis LR, Lipman RS, Covi L (1976) Self-report symptom inventory. In: Guy W (Hrsg) ECDEU assessment manual for psychopharmacology. U.S. National Institute of Health, Psychopharmacology Research Branch, Rockville, MD, S 313–331
Deutsch H (1928) Zur Genese der Platzangst. Int Z Psychoanal 14:297–314
Dieterich M, Krafczyk S, Querner V, Brandt T (2001) Somatoform phobic postural vertigo and psychogenic disorders of stance and gait. Adv Neurol 87:225–233
PubMedDilger S, Straube T, Mentzel HJ et al (2003) Brain activation to phobia-related pictures in spider phobic humans: an event-related functional magnetic resonance imaging study. Neurosci Lett 348:29–32
PubMedCrossRefDodhia S, Hosanagar A, Fitzgerald DA, Labuschagne I, Wood AG, Nathan PJ, Phan KL (2014) Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder. Neuropsychopharmacology 39:2061–2069
PubMedPubMedCentralCrossRefDomschke K, Dannlowski U (2010) Imaging genetics of anxiety disorders. Neuroimage 53:822–831
PubMedCrossRefDomschke K, Deckert J (2012) Genetics of anxiety disorders – status quo and quo vadis. Curr Pharm Des 18:5691–5698
PubMedCrossRefDomschke K, Deckert J (2017) Prävention von Angststörungen. In: Klosterkötter J, Maier W (Hrsg) Handbuch Prävention psychischer Störungen. Schattauer, Stuttgart (in Druck)
Domschke K, Zwanzger P (2008) GABAergic and endocannabinoid dysfunction in anxiety – future therapeutic targets? Curr Pharm Des 14:3508–3517
PubMedCrossRefDomschke K, Braun M, Ohrmann P, Suslow T, Kugel H, Bauer J, Hohoff C, Kersting A, Engelien A, Arolt V, Heindel W, Deckert J (2006) Association of the functional -1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. Int J Neuropsychopharmacol 9(3):349–355
PubMedCrossRefDomschke K, Stevens S, Pfleiderer B et al (2010) Interoceptive sensitivity in anxiety and anxiety disorders: an overview and integration of neurobiological findings. Clin Psychol Rev 30:1–11
PubMedCrossRefDomschke K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P, Pedersen A, Bauer J, Suslow T, Kugel H, Heindel W, Baumann C, Klauke B, Jacob C, Maier W, Fritze J, Bandelow B, Krakowitzky P, Rothermundt M, Erhardt A, Binder EB, Holsboer F, Gerlach AL, Kircher T, Lang T, Alpers GW, Ströhle A, Fehm L, Gloster AT, Wittchen HU, Arolt V, Pauli P, Hamm A, Deckert J (2011) Neuropeptide S receptor gene – converging evidence for a role in panic disorder. Mol Psychiatry 16(9):938–948
PubMedCrossRefDomschke K, Tidow N, Kuithan H, Schwarte K, Klauke B, Ambrée O, Reif A, Schmidt H, Arolt V, Kersting A, Zwanzger P, Deckert J (2012) Monoamine oxidase A gene hypomethylation – a risk factor for panic disorder? Int J Neuropsychopharmacol 15:1217–1228
PubMedCrossRefDonovan MR, Glue P, Kolluri S, Emir B (2009) Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – a meta-analysis. J Affect Disord 123:9–16
PubMedCrossRefDrenckhan I, Glöckner-Rist A, Rist F, Richter J, Gloster AT, Fehm L, Lang T, Alpers GW, Hamm AO, Fydrich T, Kircher T, Arolt V, Deckert J, Ströhle A, Wittchen HU, Gerlach AL (2015) Dimensional structure of bodily panic attack symptoms and their specific connections to panic cognitions, anxiety sensitivity and claustrophobic fears. Psychol Med 45(8):1675–1685
PubMedCrossRefDresler T, Ehlis AC, Plichta MM, Richter MM, Jabs B, Lesch KP, Fallgatter AJ (2009) Panic disorder and a possible treatment approach by means of high-frequency rTMS: a case report. World J Biol Psychiatry 10(4 Pt 3):991–997
PubMedCrossRefDresler T, Guhn A, Tupak S, Ehlis AC, Herrmann MJ, Fallgatter AF, Deckert J, Domschke K (2013) Revise the revised? – New dimensions of the neuroanatomical hypothesis of panic disorder. J Neural Transm 120:3–29
PubMedCrossRefDugas MJ (2000) Generalized anxiety disorder publications: so where do we stand? J Anxiety Disord 14:31–40
PubMedCrossRefDugas MJ, Robichaud M (2007) The cognitive-behavioral treatment of generalized anxiety disorder: from science to practice. Routledge, New York
Dugas MI, Ladouceur RLE, Ereeston M et al (2003) Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. J Consult Clin Psychol 71:821–825
PubMedCrossRefDurham RC, Chambers JA, MacDonald RR et al (2003) Does cognitive-behavioural therapy influence the long-term course of generalized anxiety disorder? An 8–14 year follow-up of two clinical trials. Psychol Med 33:499–509
PubMedCrossRefEdelman RE, Chambless DL (1993) Compliance during sessions and homework in exposure-based treatment of agoraphobia. Behav Res Ther 31:767–773
PubMedCrossRefEhlers A, Margraf J (1989) The psychophysiological model of panic attacks. In: Emmelkamp PMG, Everaerd WTAM, Kraaimaat F et al (Hrsg) Fresh perspectives on anxiety disorders. Swets & Zeitlinger, Amsterdam, S 1–29
Eley TC (2009) The genetic basis of anxiety disorders. In: Andrews G, Charney DS, Sirovatka PJ, Regier DA (Hrsg) Stress-induced and fear circuitry disorders. Advancing the research agenda for DSM-V. AMER PSYCHIATRIC PRESS, INC, Washington, DC, S 145–158
Emmelkamp PMG, Wittchen HU (2009) Specific phobias. In: Andrews G, Charney DS, Sirovatka PJ, Regier DA (Hrsg) Stress-induced and fear circuitry disorders. Advancing the research agenda for DSM-V. American Psychiatric Association, Arlington, VA, S 77–104
Emmrich A, Beesdo-Baum K, Gloster AT, Knappe S, Höfler M, Arolt V, Deckert J, Gerlach AL, Hamm A, Kircher T, Lang T, Richter J, Ströhle A, Zwanzger P, Wittchen HU (2012) Depression does not affect the treatment outcome of CBT for panic and agoraphobia: results from a multicenter randomized trial. Psychother Psychosom 81(3):161–172
PubMedCrossRefEngel K, Bandelow B, Gruber O et al (2009) Neuroimaging in anxiety disorders. J Neural Transm 116:703–716
PubMedCrossRefErhardt A, Czibere L, Roeske D, Lucae S, Unschuld PG, Ripke S, Specht M, Kohli MA, Kloiber S, Ising M, Heck A, Pfister H, Zimmermann P, Lieb R, Puetz B, Uhr M, Weber P, Deussing JM, Gonic M, Bunck M, Keßler MS, Frank E, Hohoff C, Domschke K, Krakowitzky P, Maier W, Bandelow B, Jacob C, Deckert J, Schreiber S, Strohmaier J, Noethen M, Cichon S, Rietschel M, Bettecken T, Keck ME, Landgraf R, Müller-Myhsok B, Holsboer F, Binder EB (2011) TMEM132D a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry 16:647–663
PubMedCrossRefErwin BA, Heimberg RG, Juster H, Mindlin M (2002) Comorbid anxiety and mood disorder among persons with social anxiety disorder. Behav Res Ther 40:19–35
PubMedCrossRefESEMeD/MHEDEA 2000 Investigators (2004) Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESMeD) project. Acta Psychiatr Scand 109(Suppl 420):21–27
CrossRefEtkin A, Wager TD (2007) Functional neuroimaging of anxiety: a meta-analysis of emotional processing PTSD, social anxiety disorder, and specific phobia. Am J Psychother 164:1476–1488
Evans S, Ferrando S, Findler M et al (2008) Mindfulness-based cognitive therapy for generalized anxiety disorder. J Anxiety Disord 22:716–721
PubMedCrossRefEysenck HJ (1967) The biological basis of personality. CC Thomas, Springfield
Eysenck MW (1991) Cognitive factors in clinical anxiety: potential relevance to therapy. In: Briley M, File SE (Hrsg) New concepts in anxiety. CRH Press, Boca Raton, S 418–433
CrossRefFahlen T, Nilsson HL, Borg K et al (1997) Social phobia: the clinical efficacy and tolerability of the monoamino oxidase-A and serotonin uptake inhibitor brofaromine: a double-blind, placebo-controlled study. J Clin Psychopharmacol 17:255–260
CrossRefFaravelli C, Rosi S, Truglia E (2003) Benzodiazepines. In: Nutt D, Ballenger J (Hrsg) Anxiety disorders. Blackwell, Oxford, S 315–338
Faravelli C, Furukawa TA, Truglia E (2009) Panic disorder. In: Andrews G, Charney DS, Sirovatka PJ, Regier DA (Hrsg) Stress-induced and fear circuitry disorders. Advancing the research agenda for DSM-V. American Psychiatric Association, Arlington, VA, S 31–58
Fava L, Morton J (2009) Causal modelling of panic disorder theories. Clin Psychol Rev 29:623–637
PubMedCrossRefFava GA, Zielezny M, Savron G, Grandi S (1995) Long-term effects of behavioural treatment for panic disorder with agoraphobia. Br J Psychiatry 166:87–92
PubMedCrossRefFava GA, Grandi S, Rafanelli C et al (2001) Long-term outcome of social phobia treated by exposure. Psychol Med 31:899–905
PubMedFava GA, Ruini C, Rafanelli C (2005) Sequential treatment of mood and anxiety disorders. J Clin Psychiatry 66:1392–1400
PubMedCrossRefFedoroff IC, Taylor S (2001) Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 21:311–324
PubMedCrossRefFehm L, Margraf J (2002) Thought suppression: specificity in agoraphobia versus broad impairment in social phobia? Behav Res Ther 40(1):57–66
PubMedCrossRefFehm L, Leissolo A, Furmark T, Wittchen HU (2005) Size and burden of social phobia in Europe. Eur Neuropsychopharmacol 15:453–462
PubMedCrossRefFeinstein JS, Buzza C, Hurlemann R, Follmer RL, Dahdaleh NS, Coryell WH, Welsh MJ, Tranel D, Wemmie JA (2013) Fear and panic in humans with bilateral amygdala damage. Nat Neurosci 16:270–272
PubMedPubMedCentralCrossRefFeltner DE, Crockatt JG, Dubovsky SJ et al (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23:240–249
PubMedFeltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC (2008) Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23(1):18–28
PubMedCrossRefFerguson JM, Khan A, Mangano R et al (2007) Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 68:58–68
PubMedCrossRefFeske U, Chambless DL (1995) Cognitive behaviour versus exposure treatment for social phobia: a meta-analysis. Behav Ther 26:695–720
CrossRefFisher PL (2006) The efficacy of psychological treatments for generalized anxiety disorder? In: Davey GCL, Wells A (Hrsg) Worry in its psychological disorders: theory, assessment and treatment. Wiley, Chichester, S 359–377
CrossRefFisher PL, Wells A (2009) Psychological models of worry and generalized anxiety disorder. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 225–237
Foa EM, Davidson JRT, Huppert JD et al (2003) Comprehensive CBT, fluvoxamine, and their combination: a randomized placebo-controlled trial. Annual meeting of the Association for the Advancement of Behavior Therapy, 20–23 Nov, Boston
Fonagy P, Target M (2003) Psychoanalytic theories. Perspectives from developmental psychopathology. Whurr, London/Philadelphia
Freud S (1895) Über die Berechtigung von der Neurasthenie einen bestimmten Symptomenkomplex als „Angstneurose“ abzutrennen. Gesammelte Werke, Bd 1. Fischer, Frankfurt am Main, S 315–342, 1966 ff
Freud S (1905) Drei Abhandlungen zur Sexualtheorie. GW 5:33–145
Freud S (1909) Analyse der Phobie eines fünfjährigen Knaben. GW 8:241–377
Freud S (1919) Wege der psychoanalytischen Therapie. GW 12:183–194
Freud S (1926) Hemmung, Symptom und Angst. GW 14:111–205
Furlan PM, DeMartinis N, Schweizer E et al (2001) Abnormal salivary cortisol levels in social phobic patients in response to acute psychological but not physical stress. Biol Psychiatry 50:254–259
PubMedCrossRefFurmark T, Tillfors M, Marteinsdottir I et al (2002) Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 59:425–433
PubMedCrossRefFurmark T, Tillfors M, Garpenstrand H et al (2004) Serotonin transporter polymorphism related to amygdale excitability and symptom severity in patients with social phobia. Neurosci Lett 362:189–192
PubMedCrossRefFurmark T, Carlbring P, Hedman E et al (2009) Guided and unguided self-help for social anxiety disorder: randomised controlled trial. Br J Psychiatry 195:440–447
PubMedCrossRefFurukawa TA, Watanabe N, Churchill R (2007) Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst Rev CD004364
Fyer AJ, Mannuzza S, Chapman TF et al (1995) Specificity in familial aggregation of phobic disorders. Arch Gen Psychiatry 52:564–573
PubMedCrossRefFyer AJ, Hamilton SP, Durner M et al (2006) A third-pass genome scan in panic disorder: evidence for multiple susceptibility loci. Biol Psychiatry 60:388–401
PubMedCrossRefGabbard GO (1992) Psychodynamics of panic disorder and social phobia. Bull Menninger Clin 56(Suppl A):A3–A13
PubMedGabbard GO (2005) Psychodynamic psychiatry in clinical practice, 4. Aufl. American Psychiatric Publishing, Washington, DC
Gamble AL, Harvey AG, Rapee RM (2009) Specific phobia. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 525–543
Garakani A, Murrough JW, Charney DS, Bremner D (2009) The neurobiology of anxiety disorders. In: Charney DS, Nestler EJ (Hrsg) Neurobiology of mental illness, 3. Aufl. Oxford University Press, Oxford/New York, S 655–690
Geiger M, Neufang S, Stein DJ, Domschke K (2014) Arousal and the attentional network in panic disorder. Hum Psychopharmacol 29:599–603
PubMedCrossRefGelenberg A, Lydiard RB, Rudolph R et al (2000) Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283:3082–3088
PubMedCrossRefGelernter CS, Uhde TW, Cimbolic P et al (1991) Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 48:938–945
PubMedCrossRefGerlach AL, Spellmeyer G, Vögele C, Huster R, Stevens S, Hetzel G, Deckert J (2006) Blood-injury phobia with and without a history of fainting: disgust sensitivity does not explain the fainting response. Psychosom Med 68(2):331–339
PubMedCrossRefGloster AT, Wittchen HU, Einsle F et al (2011) Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol 79(3):406–420
PubMedCrossRefGloster AT, Klotsche J, Gerlach AL, Hamm A, Ströhle A, Gauggel S, Kircher T, Alpers GW, Deckert J, Wittchen HU (2014) Timing matters: change depends on the stage of treatment in cognitive behavioral therapy for panic disorder with agoraphobia. J Consult Clin Psychol 82(1):141–153
PubMedCrossRefGoldberg DP (2014) Anxious forms of depression. Depress Anxiety 31(4):344–351
PubMedCrossRefGoldin PR, Manber T, Hakimi S et al (2009) Neural bases of social anxiety disorder: emotional reactivity and cognitive regulation during social and physical threat. Arch Gen Psychiatry 66:170–180
PubMedPubMedCentralCrossRefGoodman WK, Bose A, Wang Q (2005) Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87:161–167
PubMedCrossRefGoodwin RD, Hamilton SP (2002) Early-onset fearful panic attack: a possible prodrome of early-onset severe psychopathology. Compr Psychiatry 43:22–27
PubMedCrossRefGorman JM, Kent JM, Sullivan GM, Copan JD (2000) Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157:493–505
PubMedCrossRefGould RA, Buckminster S, Pollack MH et al (1997) Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin Psychol Sci Pract 4:291–306
CrossRefGould RA, Safren SA, Washington DON, Ott MW (2003) Cognitive-behavioral treatment for generalized anxiety disorder: a metaanalytic review. In: Mennin DS (Hrsg) Generalized anxiety disorder: advances in research and practice. Guilford, New York
Grant BF, Hasin D, Blanco C et al (2005) The epidemiology of social phobia in the United States: results form the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 66:1351–1361
PubMedCrossRefGrant BF, Hasin DS, Stinson FS et al (2006) The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results form the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 67:363–374
PubMedCrossRefGray JA (1982) Precis of the neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system. Behav Brain Sci 5:469–534
CrossRefGregory AM, Lau JYF, Eley TC (2008) Finding gene-environment interactions for phobias. Eur Arch Psychiatry Clin Neurosci 258:76–81
PubMedCrossRefGrös DF, Anthony MM (2006) The assessment and treatment of specific phobias: a review. Curr Psychiatry Rep 8:298–303
PubMedCrossRefGross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L et al (2002) Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416:396–400
PubMedCrossRefGuastella AJ, Dadds MR, Lovibond PF et al (2007) A randomized controlled trial of the effect of
d-cycloserine on exposure therapy for spider fear. J Psychiatr Res 41:466–471
PubMedCrossRefGuastella AJ, Richardson R, Lovibond PF et al (2008) A randomized controlled trial of
d-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 63:544–549
PubMedCrossRefGuastella AJ, Howard AL, Dadds MR et al (2009) A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 34:917–923
PubMedCrossRefGuhn A, Dresler T, Andreatta M, Müller LD, Hahn T, Tupak SV, Polak T, Deckert J, Herrmann MJ (2014) Medial prefrontal cortex stimulation modulates the processing of conditioned fear. Front Behav Neurosci 8:44
PubMedPubMedCentralCrossRefGuler O, Koken GN, Emul M et al (2008) Course of panic disorder during the early postpartum period: a prospective analysis. Compr Psychiatry 49:30–34
PubMedCrossRefGureje O (2008) Comorbidity of pain and anxiety disorders. Curr Psychiatry Rep 10:318–322
PubMedCrossRefHaby MM, Donnelly M, Corry J, Vos T (2006) Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome. Aust N Z J Psychiatry 40:9–19
PubMedCrossRefHackett D, Desmet A, Salinas EO (1999) Dose-response efficacy of venlafaxine XR in GAD. Poster presented at 11th world congress of psychiatry, Hamburg
Haefely W (1990) Benzodiazepine receptor and ligands: structural and functional differences. In: Hindmarch I, Beaumont G, Brandon S et al (Hrsg) Benzodiazepines: current concepts: biological, clinical and social perspectives. Wiley, Chichester, S 1–18
Hamilton M (1969) Diagnosis and rating of anxiety. In: Lader MH (Hrsg) Studies of anxiety. Br J Psychiatry (Spec Publ 3):76–79
Hamilton M (1976) The Hamilton Anxiety Scale. In: Guy W (Hrsg) ECDEU assessment manual for psychopharmacology, rev edn. U.S. National Institute of Health, Psychopharmacology Research Branch, Rockville, MD, S 193–198
Hamilton SP, Fyer AJ, Durner M et al (2003) Further genetic evidence for a panic disorder syndrome mapping to chromosome 13q. Proc Natl Acad Sci U S A 100:2550–2555
PubMedPubMedCentralCrossRefHamm A (2006) Spezifische Phobien. Fortschritte der Psychotherapie. Hogrefe, Göttingen
Hamm AO (2009) Specific phobias. Psychiatr Clin N Am 32:577–591
CrossRefHammack SE, Guo JD, Hazra R et al (2009) The response of neurons in the bed nucleus of the stria terminalis to serotonin: implications for anxiety. Prog Neuropsychopharmacol Biol Psychiatry 33:1309–1320
PubMedPubMedCentralCrossRefHansen RA, Gaynes BN, Gartlehner G (2008) Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. Int Clin Psychopharmacol 23:170–179
PubMedPubMedCentralCrossRefHarding KJ, Skritskaya N, Doherty E et al (2008) Advances in understanding illness anxiety. Curr Psychiatry Rep 10:311–317
PubMedCrossRefHariri AR, Mattay VS, Tessitore A et al (2002) Serotonin transporter genetic variation and the response of the human amygdala. Science 297:400–403
PubMedCrossRefHariri AR, Drabant EM, Munoz KE et al (2005) A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62:146–152
PubMedCrossRefHarro J (2006) CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies. Amino Acids 31:215–230
PubMedCrossRefHartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J (2007) Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22(3):167–74
PubMedCrossRefHasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, Drevets WC (2008) Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry 65(10):1166–1175
PubMedCrossRefHawgood J, De Leo D (2008) Anxiety disorders and suicidal behaviour: an update. Curr Opin Psychiatry 21:51–64
PubMedCrossRefHazlett-Stevens H, Pruitt LD, Collins A (2009) Phenomenology of generalized anxiety disorder. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 47–55
Hedges DW, Brown BL, Shwalb DA et al (2007) The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 21:102–111
PubMedCrossRefHeilig M (2004) The NPY system in stress, anxiety and depression. Neuropeptides 38:213–224
PubMedCrossRefHeimberg RG (2003) Cognitive behavioral and psychotherapeutic strategies for social anxiety disorder. Annual meeting of the Anxiety Disorders Association of America, 27–30 Mar, Toronto
Heimberg RG, Becker RE (2002) Cognitive-behavioral group therapy for social phobia: basic mechanisms and clinical strategies. Guilford, New York
Heimberg RG, Hope DA, Dodge CS et al (1990) DSM-III-R subtypes of social phobia: comparison of generalized social phobics and public speaking phobics. J Nerv Ment Dis 173:172–179
CrossRefHeimberg RG, Liebowitz MR, Hope DA et al (1998) Cognitive-behavioral group therapy vs. phenelzine therapy for social phobia: 2-week outcome. Arch Gen Psychiatry 55:1133–1141
PubMedCrossRefHeinrichs M, Domes G (2008) Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog Brain Res 170:337–350
PubMedCrossRefHelbig-Lang S, Richter J, Lang T, Gerlach AL, Fehm L, Alpers GW, Ströhle A, Kircher T, Deckert J, Gloster AT, Wittchen HU (2014) The role of safety behaviors in exposure-based treatment for panic disorder and agoraphobia: associations to symptom severity, treatment course, and outcome. J Anxiety Disord 28(8):836–844
PubMedCrossRefHettema JM (2008) What is the genetic relationship between anxiety and depression? Am J Med Genet Part C Semin Med Genet 148C:140–146
PubMedCrossRefHettema JM, Neale MC, Kendler KS (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 158:1568–1578
PubMedCrossRefHettema JM, Prescott CA, Myers JM et al (2005) The structure of genetic and environmental risk factors for anxiety disorders in men and women. Arch Gen Psychiatry 62:182–189
PubMedCrossRefHettema JM, An SS, Neale MC et al (2006a) Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism. Mol Psychiatry 11:752–762
PubMedCrossRefHettema JM, Neale MC, Myers JM et al (2006b) A population-based twin study of the relationship between neuroticism and internalizing disorders. Am J Psychiatry 163:857–864
PubMedCrossRefHidalgo RB, Tupler LA, Davidson JR (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21(8):864–72
PubMedCrossRefHicks TV, Leitenberg H, Barlow DH et al (2005) Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatment for panic disorder. J Consult Clin Psychol 73:506–514
PubMedCrossRefHirshfeld D, Smoller J, Fredman S et al (1998) Early antecedents of panic disorder. Genes, childhood, and the environment. In: Rosenbaum JF, Pollack MH (Hrsg) Panic disorder and its treatment. Marcel Dekker, New York, S 93–151
Hirshfeld-Becker DR, Micdo JA, Simoes NA, Henin A (2008) High risk studies and developmental antecedents of anxiety disorders. Am J Med Genet Part C Semin Med Genet 148C:99–117
PubMedCrossRefHoehn-Saric R, McLeod DR, Zimmerli WD (1989) Somatic manifestations in women with generalized anxiety disorder: psychophysiological responses to psychological stress. Arch Gen Psychiatry 46:1113–1119
PubMedCrossRefHoehn-Saric R, Hazlett RL, McLeod DR (1993) Generalized anxiety disorder with early and late onset of anxiety symptoms. Compr Psychiatry 34:291–298
PubMedCrossRefHoehn-Saric R, Schlund MW, Wong SH (2005) Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychiatry Res 131:11–21
CrossRefHoffmann SO (2008) Psychodynamische Therapie von Angststörungen. Einführung und Manual für die kurz- und mittelfristige Therapie. Schattauer, Stuttgart/New York
Hoffmann SO, Bassler M (1992) Psychodynamik und Psychotherapie von Angsterkrankungen. Nervenheilkunde 11:8–11
Hoffmann SO, Bassler M (1995) „Manual“ für fokal orientierte psychoanalytische Psychotherapie bei Angststörungen. Erste Erfahrungen aus einer Therapiestudie. Forum Psa 11:2–14
Hofmann SG (2007) Cognitive factors that maintain social anxiety disorder: a comprehensive model and its treatment implications. Cogn Behav Ther 36:193–209
PubMedPubMedCentralCrossRefHofmann SG, Smits JA (2008) Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 69:621–632
PubMedPubMedCentralCrossRefHofmann SG, Meuret AE, Smits JA et al (2006) Augmentation of exposure therapy with
d-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63:298–304
PubMedCrossRefHofmann SG, Sawyer AT, Korte KJ, Smits JA (2009) Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther 2:160–175
PubMedPubMedCentralCrossRefHolsboer F, Ising M (2008) Central CRH system in depression and anxiety – evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583:350–357
PubMedCrossRefHood S, Potokar J, Davies S et al (2010) Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants. J Psychopharmacol 24:709–716
PubMedCrossRefHope DA, Heimberg RG, Turk CL (2006) Managing social anxiety: a cognitive-behavioral therapy approach (therapist guide). Oxford University Press, Oxford/New York
Hunot V, Churchill R, Silva de Lima M, Teixeira V (2007) Psychological therapies for generalized anxiety disorder. Cochrane Database Syst Rev CD001848
Huppert JD, Sanderson WC (2009) Psychotherapy for generalized anxiety disorder. In: Stein DJ, Hollander E, Rothbaum BO (Hrsg) Anxiety disorders, 2. Aufl. American Psychiatric Publishing, Washington, DC/London, S 219–238
Huppert D, Strupp M, Rettinger N et al (2005) Phobic postural vertigo – a long-term follow-up (5 to 15 years) of 106 patients. J Neurol 252:564–569
PubMedCrossRefIpser JC, Kariuki CM, Stein DJ (2008) Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 8:235–257
PubMedCrossRefJacob RG, Redfern MS, Furman JM (2009) Space and motion discomfort and abnormal balance control in patients with anxiety disorders. J Neurol Neurosurg Psychiatry 80:74–78
PubMedCrossRefJennings JH, Sparta DR, Stamatakis AM, Ung RL, Pleil KE, Kash TL, Stuber GD (2013) Distinct extended amygdala circuits for divergent motivational states. Nature 496:224–228
PubMedPubMedCentralCrossRefJoëls M, Baram TZ (2009) The neuro-symphony of stress. Nat Rev Neurosci 10:459–466
PubMedPubMedCentralJoyce M, Khan A, Atkinson S et al (2008) Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD). Poster presented at the annual meeting of the American Psychiatric, Washington, DC
Kaabi B, Gelernter J, Woods SW et al (2006) Genome scan for loci predisposing to anxiety disorders using a novel multivariate approach: strong evidence for a chromosome 4 risk locus. Am J Hum Genet 78:543–553
PubMedPubMedCentralCrossRefKagan J (1989) Temperamental contributions to social behavior. Am Psychol 44:668–674
CrossRefKalueff AV, Nutt DJ (2007) Role of GABA in anxiety and depression. Depress Anxiety 24:495–517
PubMedCrossRefKampman M, Keijsers GPJ, Hoogduin CAL, Hendriks GJ (2002) A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry 63:772–777
PubMedCrossRefKamprath K, Romo-Parra H, Häring M, Gaburro S, Doengi M, Lutz B, Pape HC (2011) Short-term adaptation of conditioned fear responses through endocannabinoid signaling in the central amygdala. Neuropsychopharmacology 36(3):652–663
PubMedCrossRefKapfhammer HP (2010) Psychotherapie und Pharmakotherapie. In: Adler RA, Joraschky P, Köhle K et al (Hrsg) Uexküll Psychosomatische Medizin. Modelle ärztlichen Denkens und Handelns, 7. Aufl. Urban & Fischer, München/Jena (im Druck)
Kapfhammer HP, Fitz W, Huppert D, Grill E, Brandt T (2015) Acrophobia and visual height intolerance within conditions of anxiety and depression. Eur Arch Psychiatry Clin Neurosci 265:375–385
PubMedCrossRefKaplan JR, Manuck SB, Fontenot MB, Mann JJ (2002) Central nervous system monoamine correlates of social dominance in cynomolgus monkeys (
Macaca fascicularis). Neuropsychopharmacology 26:431–443
PubMedCrossRefKasper S, Herman B, Nivoli G et al (2009) Efficacy of pregabalin and venlafaxine XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24:87–96
PubMedCrossRefKasper S, Gastpar M, Müller WE, Volz HP, Möller HJ, Schläfke S, Dienel A (2014) Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 17(6):859–869
PubMedCrossRefKästner N, Richter SH, Lesch KP, Schreiber RS, Kaiser S, Sachser N (2015) Benefits of a „vulnerability gene“? A study in serotonin transporter knockout mice. Behav Brain Res 283:116–120
PubMedCrossRefKaton WJ (2006) Panic disorder. N Engl J Med 354:2360–2367
PubMedCrossRefKatschnig H, Amering M (1994) The long-term course of panic disorder. In: Wolfe BE, Maser JD (Hrsg) Treatment of panic disorder. A consensus development conference. American Psychiatric Press, Washington, DC/London, S 73–81
Katschnig H, Stein MB, Buller R, The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia (1997) Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 247:71–80
CrossRefKatz IR, Reynolds CF 3rd, Alexopoulos GS et al (2002) Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 50:18–25
PubMedCrossRefKatzelnick DJ, Kobak KA, DeLeire T et al (2001) Impact of generalized social anxiety disorder in managed care. Am J Psychiatry 158:1999–2007
PubMedCrossRefKatzman MA (2009) Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 23:103–120
PubMedCrossRefKeck ME, Ströhle A (2005) Challenge studies in anxiety disorders. Handb Exp Pharmacol 169:449–468
Keller MB (2006) Social anxiety disorder clinical course and outcome: review of Harvard/Brown/Anxiety Research Project (HARP) findings. J Clin Psychiatry 12:14–19
Kendler KS (1996) Major depression and generalized anxiety disorder: same genes, (partly) different environments – revisited. Br J Psychiatry 49:267–272
Kendler KS, Neale M, Kessler R et al (1992a) The genetic epidemiology of phobias in women: the interrelationship of agoraphobia, social phobia, situational phobia and simple phobia. Arch Gen Psychiatry 49:273–281
PubMedCrossRefKendler KS, Karkowski LM, Prescott CA (1999) Fears and phobias: reliability and heritability. Psychol Med 29:539–553
PubMedCrossRefKendler KS, Myers J, Prescott CA, Neale MC (2001) The genetic epidemiology of irrational fears and phobias in men. Arch Gen Psychiatry 58:257–265
PubMedCrossRefKendler KS, Jacobson KC, Myers J, Prescott CA (2002) Sex differences in genetic and environmental risk factors for irrational fears and phobias. Psychol Med 32:209–217
PubMedCrossRefKent JM, Mathew SJ, Gorman JM (2002) Molecular targets in the treatment of anxiety. Biol Psychiatry 52:1008–1030
PubMedCrossRefKessler RC, Berglund P, Demler O et al (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593–602
PubMedCrossRefKessler RC, Ruscio AM, Shear K, Wittchen HU (2009) Epidemiology of anxiety disorders. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 19–33
Kilts CD, Kelsey JE, Knight BT et al (2006) The neural correlates of social anxiety disorder and response to pharmacotherapy. Neuropsychopharmacology 31:2243–2253
PubMedCrossRefKim TS, Pae CU, Yoon SJ et al (2006) Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci 60:347–351
PubMedCrossRefKim YW, Lee SH, Choi TK et al (2009) Effectiveness of mindfulness-based cognitive therapy as an adjuvant to pharmacotherapy in patients with panic disorder or generalized anxiety disorder. Depress Anxiety 26:601–606
PubMedCrossRefKim SY, Adhikari A, Lee SY, Marshel JH, Kim CK, Mallory CS, Lo M, Pak S, Mattis J, Lim BK, Malenka RC, Warden MR, Neve R, Tye KM, Deisseroth K (2013) Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature 496:219–223
PubMedCrossRefKircanski K, Craske MG, Epstein AM, Wittchen HU (2009) Subtypes of panic attacks: a critical review of the empirical literature. Depress Anxiety 26:878–887
PubMedCrossRefKlauke B, Deckert J, Reif A, Pauli P, Domschke K (2010) Life events in panic disorder-an update on „candidate stressors“. Depress Anxiety 27(8):716–730
PubMedKlauke B, Deckert J, Reif A, Pauli P, Zwanzger P, Baumann C, Arolt V, Glöckner-Rist A, Domschke K (2011) Serotonin transporter gene and childhood trauma – a GxE effect on anxiety sensitivity. Depress Anxiety 28:1048–1057
PubMedCrossRefKlein DF (1964) Delineation of two drug responsive anxiety syndromes. Psychopharmacologica (Berl) 5:397–408
CrossRefKlein DF (1993) False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry 50:306–317
PubMedCrossRefKlein DF (2002) Response differences of spontaneous panic and fear. Arch Gen Psychiatry 59:567–569
PubMedCrossRefKlein DF, Klein HM (1988) The status of panic disorder. Curr Opin Psychiatry 1:177–183
Klein C, Milrod B, Busch F et al (2003) A process-outcome study of panic-focused psychodynamic psychotherapy. Psychoanal Inq 23:308–331
CrossRefKlose M, Jacobi F (2004) Can gender differences in the prevalence of mental disorders be explained by sociodemographic factors? Arch Womens Ment Health 7:133–148
PubMedCrossRefKnappe S, Beesdo K, Fehm L et al (2009) Associations of familial risk factors with social fears and social phobia: evidence for the continuum hypothesis in social anxiety disorder? J Neural Transm 116:639–648
PubMedCrossRefKobak KA, Griest JH, Jefferson JW, Katzelnick DJ (2002) Fluoxetine in social phobia: a double blind, placebo-controlled pilot study. J Clin Psychopharmacol 22:257–262
PubMedCrossRefKoenen KC, Amstadter AB, Ruggiero KJ et al (2009) RGS2 and generalized anxiety disorder in an epidemiologic sample of hurricane-exposed adults. Depress Anxiety 26:309–315
PubMedPubMedCentralCrossRefKoenigs M, Grafman J (2009) Posttraumatic stress disorder: the role of medial prefrontal cortex and amygdale. Neuroscientist 15:540–548
PubMedPubMedCentralCrossRefKoponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, Ball SG, Russell JM (2007) Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 9(2):100–7
PubMedPubMedCentralCrossRefvon Korff MR, Eaton WW, Keyl PM (1985) The epidemiology of panic attacks and panic disorder: results of three community surveys. Am J Epidemiol 122:970–981
CrossRefKossowsky J, Pfaltz MC, Schneider S, Taeymans J, Locher C, Gaab J (2013) The separation anxiety hypothesis of panic disorder revisited: a meta-analysis. Am J Psychiatry 170:768–781
PubMedCrossRefKrieg JC, Bronisch T, Wittchen HU et al (1987) Anxiety disorders: a long-term prospective and retrospective follow-up study of former inpatients suffering from an anxiety neurosis or phobia. Acta Psychiatr Scand 76:36–47
PubMedCrossRefKroenke K, Messina N, Benattia I et al (2006) Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry 67:72–80
PubMedCrossRefKushner MG, Beitman BD (1990) Panic attacks without fear: an overview. Behav Res Ther 28:469–479
PubMedCrossRefKuzma JM, Black DW (2004) Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders. Curr Psychiatry Rep 6:268–273
PubMedCrossRefKönig K (1981) Angst und Persönlichkeit. Das Konzept vom steuernden Objekt und seine Anwendungen. Vandenhoeck & Ruprecht, Göttingen
LaBar KS, Cabeza R (2006) Cognitive neuroscience of emotional memory. Nat Rev Neurosci 7:54–64
PubMedCrossRefLader MH, Gelder MG, Marks IM (1967) Palmar skin conductance measures as predictors of response to desensitization. J Psychosom Res 11:283–290
PubMedCrossRefLader M, Scotto JC (1998) A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 139(4):402–6
CrossRefLader M, Stender K, Bürger V, Nil R (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19(4):241–8
PubMedCrossRefLanzenberger RR, Mitterhauser M, Spindelegger C et al (2007) Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 61:1081–1089
PubMedCrossRefLarson CL, Schaefer HS, Siegle GJ et al (2006) Fear is fast in phobic individuals: amygdala activation in response to fear-relevant stimuli. Biol Psychiatry 60:410–417
PubMedCrossRefLau JY, Pine DS (2008) Elucidating risk mechanisms of gene environment interactions on pediatric anxiety: integrating findings from neuroscience. Eur Arch Psychiatry Clin Neurosci 258:97–106
PubMedCrossRefLaugharne J, Lillee A, Janca A (2010) Role of psychological trauma in the cause and treatment of anxiety and depressive disorders. Curr Opin Psychiatry 23:25–29
PubMedCrossRefLawrence AE, Brown TA (2009) Classification and boundaries among anxiety-related problems. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 265–276
Leahy RL, MvGinn LK, Busch FN, Milrod BL (2005) Anxiety disorders. In: Gabbard GO, Beck JS, Holmes J (Hrsg) Oxford textbook of psychotherapy. Oxford University Press, Oxford, S 137–161
Ledgerwood L, Richardson R, Cranney J (2005) D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry 57(8):841–7
PubMedCrossRefLeDoux J (1998) The neural circuits underlying anxiety and fear. Biol Psychiatry 44:1229–1238
PubMedCrossRefLeenstra AS, Ormel J, Giel R (1995) Positive life change and recovery from depression and anxiety: a three-stage longitudinal study of primary care attenders. Br J Psychiatry 166:333–343
PubMedCrossRefLeichsenring F, Winkelbach C, Leibing E (2002) Die Generalisierte Angststörung – Krankheitsmuster, Diagnostik und Therapie. Z Psychosom Med Psychother 48:235–255
PubMedLeichsenring F, Rabung S, Leibing E (2004) The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 61:1208–1216
PubMedCrossRefLeichsenring F, Winkelbach C, Leibing E (2005) Psychoanalytisch-orientierte Fokaltherapie der Generalisierten Angststörung. Ein Manual. Psychotherapeut 50:258–264
CrossRefLeichsenring F, Salzer S, Jaeger U et al (2009a) Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry 166:875–881
PubMedCrossRefLeichsenring F, Salzer S, Beutel ME (2009b) SOPHO-NET – Forschungsverbund zur Psychotherapie der sozialen Phobie. Psychother Psychosom Med Psychol 59:117–123
PubMedCrossRefLeichsenring F, Salzer S, Beutel ME, Herpertz S, Hiller W, Hoyer J, Huesing J, Joraschky P, Nolting B, Poehlmann K, Ritter V, Stangier U, Strauss B, Stuhldreher N, Tefikow S, Teismann T, Willutzki U, Wiltink J, Leibing E (2013) Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: a multicenter randomized controlled trial. Am J Psychiatry 170:759–767
PubMedCrossRefLenox-Smith AJ, Reynolds A (2003) A double-blind, randomised, placebo-controlled study of venlafaxine XR in patients with generalized anxiety disorder in primary care. Br J Gen Pract 53:772–777
PubMedPubMedCentralLenze EJ (2009) Anxiety disorders in the elderly. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 651–664
Lenze EJ, Mulsant BH, Shear MK et al (2005) Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry 162:146–150
PubMedCrossRefLeonardo ED, Hen R (2006) Genetics of affective and anxiety disorders. Annu Rev Psychol 57:117–137
PubMedCrossRefLesch KP, Bengel D, Heils A et al (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527–1531
PubMedCrossRefLevin FM (2009) Emotion and the psychodynamics of the cerebellum. A neuro-psychoanalytic analysis and synthesis. Karnac, London
Levitan MN, Nardi AE (2009) Nocturnal panic attacks: clinical features and respiratory connections. Expert Rev Neurother 9(2):245–254
PubMedCrossRefLieb R, Becker E, Altamura C (2005) The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 15:445–452
PubMedCrossRefLiebowitz MR (1987) Social phobia. Mod Probl Pharmacopsychiatry 22:141–173
PubMedCrossRefLiebowitz MR, Schneider F, Campeas R et al (1992) Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 49:290–300
PubMedCrossRefLiebowitz MR, Mangano RM, Bradwein J, Asnis G (2005c) A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238–247
PubMedCrossRefLiebowitz MR, Asnis G, Mangano R, Tzanis E (2009) A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. J Clin Psychiatry 70:550–561
PubMedCrossRefLinden M, Zubrägel D, Bär T et al (2005) Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychother Psychosom 74:36–42
PubMedCrossRefLipsitz JD, Gur M, Miller NL et al (2006) An open pilot study of interpersonal psychotherapy for panic disorder. J Nerv Ment Dis 194:440–445
PubMedCrossRefLipsitz JD, Gur M, Vermes D et al (2008) A randomized trial of interpersonal psychotherapy versus supportive therapy of social anxiety disorder. Depress Anxiety 25:542–553
PubMedCrossRefLlorca PM, Spadone C, Sol O et al (2002) Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 63:1020–1027
PubMedCrossRefLorberbaum JP, Kose S, Johnson MR et al (2004) Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport 15:2701–2705
PubMedLott M, Greist JH, Jefferson JW et al (1997) Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 17:55–260
CrossRefLueken U, Straube B, Konrad C, Wittchen HU, Ströhle A, Wittmann A, Pfleiderer B, Uhlmann C, Arolt V, Jansen A, Kircher T (2013) Neural substrates of treatment response to cognitive-behavioral therapy in panic disorder with agoraphobia. Am J Psychiatry 170(11):1345–1355
PubMedCrossRefLydiard RB, Rickels K, Herman B, Feltner DE (2009) Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 9:1–13
Machado S, Santos V, Paes F, Arias-Carrión O, Carta MG, Silva AC, Nardi AE (2014) Repetitive transcranial magnetic stimulation (rTMS) to treat refractory panic disorder patient: a case report. CNS Neurol Disord Drug Targets 13(6):1075–1078
PubMedCrossRefMagee WJ, Eaton WW, Wittchen HU et al (1996) Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53:159–168
PubMedCrossRefMagee L, Erwin BA, Heimberg RG (2009) Psychological treatment of social anxiety disorder and specific phobia. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 334–349
Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y (2014a) A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol 29:64–72
PubMedCrossRefMahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS (2014b) A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract 68:49–59
PubMedCrossRefMakara GB, Mergl Z, Zelena D (2004) The role of vasopressin in hypothalamo-pituitary-adrenal axis activation during stress: an assessment of the evidence. Ann N Y Acad Sci 1018:151–161
PubMedCrossRefMalizia AL, Wilson SJ, Bell CM et al (1997) Neural correlates of anxiety provocation in social phobia. Neuroimage 5:301–305
Marcin MS, Nemeroff CB (2003) The neurobiology of social anxiety disorder: the relevance of fear and anxiety. Acta Psychiatr Scand 108(Suppl 417):51–64
CrossRefMargraf J, Ehlers A (1989) Etiological models of panic – psychophysiological and cognitive aspects. In: Baker R (Hrsg) Panic disorder: research and therapy. Wiley, London, S 205–231
Marks IM (1987) Fears, phobias and rituals. Oxford University Press, New York
Marks IM (1988) Blood-injury phobia: a review. Am J Psychiatry 145:1207–1214
PubMedCrossRefMarks IM, Swinson RP, Basoglu M et al (1993) Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiatry 162:776–778
PubMedCrossRefMaron E, Shlik J (2006) Serotonin function in panic disorder: important, but why? Neuropsychopharmacology 31:1–11
PubMedCrossRefMaron E, Kuikka JT, Ulst K et al (2004) SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur Arch Psychiatry Clin Neurosci 254:392–396
PubMedCrossRefMarshall RD (1995) Integrated treatment of social phobia. Bull Menninger Clin 59(Suppl A):A27–A37
PubMedMarteinsdottir I, Svensson A, Svedberg M et al (2007) The role of life events in social phobia. Nord J Psychiatry 61:207–212
PubMedCrossRefMartin EI, Ressler KJ, Binder E, Nemeroff CB (2009) The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin N Am 32:549–575
CrossRefMathew SJ, Ho S (2006) Etiology and neurobiology of social anxiety disorder. J Clin Psychiatry 12:9–13
Mathew SJ, Coplan JD, Gorman JM (2001) Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 158:1558–1567
PubMedCrossRefMathew SJ, Amiel JM, Coplan JD et al (2005) Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162:2379–2381
PubMedCrossRefMathew SJ, Price RB, Charney DS (2008) Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet Part C Semin Med Genet 148C:89–98
PubMedCrossRefMcCabe RE, Gifford S (2009) Psychological treatment of panic disorder and agoraphobia. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 308–320
McGrath M, Kawachi I, Ascherio A et al (2004) Association between catechol-
O-methyltransferase and phobic anxiety. Am J Psychiatry 161:1703–1705
PubMedCrossRefMcHugh RK, Smits JA, Otto MW (2009) Empirically supported treatments for panic disorder. Psychiatr Clin North Am 32:593–610
PubMedCrossRefMcLean CP, Anderson ER (2009) Brave men and timid women? A review of the gender differences in fear and anxiety. Clin Psychol Rev 29:496–505
PubMedCrossRefMcNally RJ (1994) Choking phobia: a review of the literature. Compr Psychiatry 35:83–89
PubMedCrossRefMcNally RJ, Eke M (1996) Anxiety sensitivity, suffocation fear, and breath-holding duration as predictors of response to carbon dioxide challenge. J Abnorm Psychol 105:146–149
PubMedCrossRefMcNally RJ, Reese HE (2009) Information-processing approaches to understanding anxiety disorders. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 136–152
Meissner WW (1991) Aggression in phobic states. Psychoanal Inq 11:261–283
CrossRefMentzos S (1984) Angstneurose. Psychodynamische und psychotherapeutische Aspekte. Fischer, Frankfurt/Main
Mentzos S (2009) Lehrbuch der Psychodynamik. Die Funktion der Funktionalität psychischer Störungen. Vandenhoeck & Ruprecht, Göttingen
Merikangas KR, Avenevoli S, Acharyya S et al (2002) The spectrum of social phobia in the Zürich cohort study of young adults. Biol Psychiatry 51:81–91
PubMedCrossRefMeyer JK, Maletic V (1991) The clinical and theoretical structures of adult phobias. Psychoanal Inq 11:333–350
CrossRefMeyer-Lindenberg A (2008) Impact of prosocial neuropeptides on human brain function. Prog Brain Res 170:463–470
PubMedCrossRefMiller LA, Taber KH, Gabbard GO, Hurley RA (2005) Neural underpinnings of fear and its modulation: implications. J Neuropsychiatry Clin Neurosci 17:1–6
PubMedCrossRefMilrod BL, Shear MK (1991a) Dynamic treatment of panic disorder: a review. J Nerv Ment Dis 179:741–743
PubMedCrossRefMilrod BL, Shear MK (1991b) Psychodynamic treatment of panic: three case histories. Hosp Community Psychiatry 42:311–312
PubMedMilrod BL, Busch F, Cooper A, Shapiro T (1997) Manual of panic-focused psychodynamic psychotherapy. American Psychiatric Press, Washington, DC/London
Milrod B, Busch F, Leon AC et al (2000) Open trial of psychodynamic psychotherapy for panic disorder: a pilot study. Am J Psychiatry 157:1878–1880
PubMedCrossRefMilrod B, Busch F, Leon AC et al (2001) A pilot open trial of brief psychodynamic psychotherapy for panic disorder. J Psychother Pract Res 10:239–245
PubMedPubMedCentralMilrod B, Leon AC, Busch F et al (2007) A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. Am J Psychiatry 164:265–272
PubMedCrossRefMineka S, Zinbarg R (2006) A contemporary learning theory perspective on the etiology of anxiety disorders: it’s not what you thought it was. Am Psychol 61:10–26
PubMedCrossRefMirza NR, Bright JL, Stanhope KJ et al (2005) Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? Psychopharmacology (Berl) 180:159–168
CrossRefMitte K (2005) A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 88:27–45
PubMedCrossRefMitte K, Noack P, Steil R, Hautzinger M (2005) A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25:141–150
PubMedCrossRefMoffitt TE, Harrington H, Caspi A et al (2007) Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Arch Gen Psychiatry 64:651–660
PubMedCrossRefMöhler H, Fritschy JM, Crestani F et al (2004) Specific GABAA circuits in brain development and therapy. Biochem Pharmacol 68:1685–1690
PubMedCrossRefMöller HJ, Volz HP, Reimann IW, Stoll KD (2001) Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21:59–65
PubMedCrossRefMontgomery SA, Nil R, Durr-Pal N et al (2005) A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270–1278
PubMedCrossRefMontgomery SA, Tobias K, Zornberg GL et al (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771–782
PubMedCrossRefMontgomery S, Chatamra K, Pauer L et al (2008) Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 193:389–394
PubMedCrossRefMorreale M, Tancer ME, Uhde TW (2009) Pathogenesis of social anxiety disorder. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 453–469
Morris EP, Stewart SH, Ham LS (2005) The relationship between social anxiety disorder and alcohol use disorders: a critical review. Clin Psychol Rev 25:734–760
PubMedCrossRefMorrison KH, Bradley R, Westen D (2003) The external validity of controlled clinical trials of psychotherapy for depression and anxiety: a naturalistic study. Psychol Psychother 76:109–132
PubMedCrossRefMowrer OH (1947) On the dual nature of learning – a reinterpretation of „conditioning“ and „problem solving“. Harv Educ Rev 17:102–148
Mühlbacher M, Nickel MK, Nickel C et al (2005) Mirtazapine treatment of social phobia in women: a randomized, double-blind placebo-controlled study. J Clin Psychopharmacol 25:580–583
CrossRefMunjack DJ, Baltazar PL, DeQuattro V et al (1990) Generalized anxiety disorder: some biochemical aspects. Psychiatry Res 32:35–43
PubMedCrossRefMurray L, Creswell C, Cooper PJ (2009) The development of anxiety disorders in childhood: an integrative review. Psychol Med 39:1413–1423
PubMedCrossRefMurray CJ, Abraham J, Ali MK, Alvarado M, Atkinson C, Baddour LM, US Burden of Disease Collaborators et al (2013) The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA 310:591–608
PubMedCrossRefNardi AE, Lopes FL, Freire RC et al (2009) Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. Psychiatry Res 169:149–153
PubMedCrossRefNemeroff CB (2003) The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37:133–146
PubMedNemiah JC (1981) A psychoanalytic view of phobias. Am J Psychoanal 41:115–120
PubMedCrossRefNeumeister A, Bain E, Nugent AC et al (2004) Reduced serotonin 1A receptor binding in panic disorder. J Neurosci 24:589–591
PubMedCrossRefNeumeister A, Daher RJ, Charney DS (2005) Anxiety disorders: noradrenergic neurotransmission. Handb Exp Pharmacol 169:205–223
Newman MG, Castonguay LG, Borkovec TD, Molnar C (2004) Integrative psychotherapy. In: Heimberg RG, Turk CL (Hrsg) Generalized anxiety disorder: advances in research and practice. Guilford, New York, S 320–350
Nimatoudis I, Zissis NP, Kogeorgos J et al (2004) Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder: a double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 19:331–336
PubMedCrossRefNinan PT, Dunlop BW (2005) Neurobiology and etiology of panic disorder. J Clin Psychiatry 66(Suppl 4):3–7
PubMedNitschke JB, Sarinopoulos I, Oathes DJ et al (2009) Anticipatory activation in the amygdale and anterior cingulated in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry 166:302–310
PubMedPubMedCentralCrossRefNorrholm SD, Ressler KJ (2009) Genetics of anxiety and trauma-related disorders. Neuroscience 134:272–287
CrossRefNoyes R, Hoehn-Saric R (1998) The anxiety disorders. Cambridge University Press, Cambridge
CrossRefNoyes R, Reich J, Christiansen J et al (1990) Outcome of panic disorder: relationship to diagnostic subtypes and comorbidity. Arch Gen Psychiatry 47:809–818
PubMedCrossRefNoyes R, Woodman C, Garvewy MJ et al (1992) Generalized anxiety disorder vs. panic disorder: distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis 180:369–379
PubMedCrossRefNoyes R, Moroz G, Davidson JRT et al (1997) Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 17:247–254
PubMedCrossRefNutt DJ (2001) Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 62(Suppl 11):22–27
PubMedNutt DJ (2005) Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 10:49–56
PubMedCrossRefNutt DJ, Malizia AL (2001) New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390–396
PubMedCrossRefNutt DJ, Forshalll S, Bell C et al (1999) Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 9:S81–S86
PubMedCrossRefOhara K, Suzuki Y, Ochiai M et al (1999) A variable-number-tandem-repeat of the serotonin transporter gene and anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry 23:55–65
PubMedCrossRefÖhman A, Mineka S (2001) Fears, phobias, and preparedness: toward an evolved module of fear and fear learning. Psychol Rep 198:483–522
CrossRefOlatunji BO, Wolitzky-Taylor KB (2009) Anxiety sensitivity and the anxiety disorder: a meta-analytic review and synthesis. Psychol Bull 135:974–999
PubMedCrossRefOlatunji BO, Forsyth JP, Cherian A (2007) Evaluative differential conditioning of disgust: a sticky form or relational learning that is resistant to extinction. J Anxiety Disord 21:820–834
PubMedCrossRefOlesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19:155–162
PubMedCrossRefOlivier B, van Wijngaarden I, Soudijn W (2000) 5-HT3 receptor antagonists and anxiety: a preclinical and clinical view. Eur Neuropsychopharmacol 10:77–95
PubMedCrossRefOlsson A, Nearing KI, Phelps EA (2007) Learning fears by observing others: the neural systems of social fear transmission. Soc Cogn Affect Neurosci 2:3–12
PubMedPubMedCentralCrossRefOosterink FM, de Jongh A, Hoogstraten J (2009) Prevalence of dental fear and phobia relative to other fear and phobia subtypes. Eur J Oral Sci 117:135–143
PubMedCrossRefOpris D, Pintea S, Garcia-Palacios A, Botella C, Szamoskozi S, David D (2012) Virtual reality exposure therapy in anxiety disorders: a quantitative meta-analysis. Depress Anxiety 29:85–93
PubMedCrossRefOrmel J, Oldehinkel T, Brilman E (1993) Outcome of depression and anxiety in primary care. Arch Gen Psychiatry 50:759–766
PubMedCrossRefÖst LG (1997) Rapid treatment of specific phobias. In: Davey GCL (Hrsg) Phobias. Wiley, New York, S 227–246
Öst LG (2000) Spezifische Phobien. In: Margraf J (Hrsg) Lehrbuch der Verhaltenstherapie, Bd 2, 2. Aufl. Springer, Berlin/Heidelberg/New York/Tokio, S 29–42
CrossRefÖst LG (2008) Efficacy of the third wave of behavioral therapies: a systematic review and meta-analysis. Behav Res Ther 46(3):296–321
PubMedCrossRefOtto MW, Powers M, Smits JAJ (2005) Adding cognitive-behavioral therapy to pharmacotherapy for panic disorder. Issues and strategies. CNS Spectr 9:32–39
CrossRefOtto MW, Behar E, Smits JAJ, Hofmann ST (2009) Combining pharmacological and cognitive behavioral therapy in the treatment of anxiety disorders. In: Stein DJ, Hollander E, Rothbaum BO (Hrsg) Anxiety disorders, 2. Aufl. American Psychiatric Publishing, Washington, DC/London, S 429–440
Otto MW, Tolin DF, Simon NM et al (2010) Efficacy of
d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67:365–370
PubMedCrossRefOuimet AJ, Gawronski B, Dozois DJ (2009) Cognitive vulnerability to anxiety: a review and an integrative model. Clin Psychol Rev 29:459–470
PubMedCrossRefOyebode F (2008) Sim’s symptoms in the mind. An introduction to descriptive psychopathology, 4. Aufl. Saunders, Elsevier, Edinburgh/London/New York
Palombo J, Bendicsen HK, Koch BJ (2009) Guide to psychoanalytic developmental theories. Springer, Berlin/Heidelberg/New York
Pande AC, Davidson JR, Jefferson JW et al (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341–348
PubMedCrossRefPande AC, Crockatt JG, Feltner DE et al (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160:533–540
PubMedCrossRefPande AC, Feltner DE, Jefferson JW et al (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebocontrolled, multicenter study. J Clin Psychopharmacol 24:141–149
PubMedCrossRefPané-Farré CA, Stender JP, Fenske K, Deckert J, Reif A, John U, Schmidt CO, Schulz A, Lang T, Alpers GW, Kircher T, Vossbeck-Elsebusch AN, Grabe HJ, Hamm AO (2014) The phenomenology of the first panic attack in clinical and community-based samples. J Anxiety Disord 28(6):522–529. doi:10.1016/j.janxdis.2014.05.009. Epub 2 June 2014
Panksepp J (1998) Affective neuroscience. The foundations of human and animal emotions. Oxford University Press, Oxford
Papazisis G, Tzachanis D (2014) Pregabalin’s abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther 52:709–716
PubMedCrossRefPape HC, Jüngling K, Seidenbecher T, Lesting J, Reinscheid RK (2010) Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropharmacology 58(1):29–34
PubMedCrossRefPaquette V, Levesque J, Mensour B et al (2003) Change the mind and you change the brain: effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage 18:401–409
PubMedCrossRefPaulus MP, Stein MB (2006) An insular view of anxiety. Biol Psychiatry 60:383–387
PubMedCrossRefPerna G, Dario A, Caldirola D et al (2001) Panic disorder: the role of balance system. J Psychiatr Res 35:279–286
PubMedCrossRefPeterson RA, Reiss S (1987) Anxiety sensitivity index manual. International Diagnostic Systems, Orland Park
Pezewas L, Meyer-Lindenberg A, Drabant EM et al (2005) 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8:828–834
CrossRefPfleiderer B, Zinkirciran S, Arolt V, Heindel W, Deckert J, Domschke K (2007) fMRI amygdala activation during a spontaneous panic attack in a patient with panic disorder. World J Biol Psychiatry 8(4):269–272
PubMedCrossRefPhan KL, Fitzgerald DA, Nathan PJ, Tancer ME (2006) Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry 59:424–429
PubMedCrossRefPissiota A, Frans O, Michelgard A et al (2003) Amygdala and anterior cingulated cortex activation during affective startle modulation: a PET study of fear. Eur J Neurosci 18:1325–1331
PubMedCrossRefPohl R, Yeragani VK, Balon R (1988) Isoproterenol-induced panic attacks. Biol Psychiatry 24:891–902
PubMedCrossRefPohl RB, Feltner DE, Fieve RR, Pande AC (2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25:151–158
PubMedCrossRefPollack MH (2005) The pharmacotherapy of panic disorder. J Clin Psychiatry 66(Suppl 4):23–27
PubMedPollack MH (2009) Refractory generalized anxiety disorder. J Clin Psychiatry 2:32–38
CrossRefPollack MH, Otto MW, Sabatino S et al (1996) Relationship of childhood anxiety to adult panic disorder: correlates and influence on course. Am J Psychiatry 153:376–381
PubMedCrossRefPollack MH, Zaninelli R, Goddard A et al (2001) Paroxetine in the treatment of generalized anxiety disorder: results of a placebo controlled, flexible-dosage trial. J Clin Psychiatry 62:350–357
PubMedCrossRefPollack MH, Simon NM, Zalta AK et al (2006) Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59:211–215
PubMedCrossRefPollack M, Mangano R, Entsuah R et al (2007) A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 194:233–242
CrossRefPonniah K, Hollon SD (2008) Empirically supported psychological interventions for social phobia in adults: a qualitative review of randomized controlled trials. Psychol Med 38:3–14
PubMedCrossRefPontoski KE, Heimberg RG, Turk CL, Coles M (2009) Psychotherapy for social anxiety disorder. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 501–521
Poulton R, Menzies RG (2002) Non-associative fear acquisition: a review of the evidence from retrospective and longitudinal research. Behav Res Ther 40:127–149
PubMedCrossRefPowers MB, Smits JA, Otto MW et al (2009) Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 23:350–356
PubMedCrossRefPrasko J, Dockery C, Horacek J et al (2006) Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett 27(4):473–481
PubMedRachman S (1977) The conditioning theory of fear-acquisition: a critical examination. Behav Res Ther 15:375–387
PubMedCrossRefRachman SJ (1991) Neoconditioning and the classical theory of fear acquisition. Clin Psychol Rev 11:155–173
CrossRefRaffa SD, Stoddard JA, White KS (2008) Relapse following combined treatment discontinuation in a placebo controlled trial for panic disorder. J Nerv Ment Dis 196:548–555
PubMedCrossRefRapee RM (2013) The preventative effects of a brief, early intervention for preschool-aged children at risk for internalising: follow-up into middle adolescence. J Child Psychol Psychiatry 54:780–788
PubMedCrossRefRapee RM, Bryant RA (2009) Stress and psychosocial factors in onset of fear circuitry disorders. In: Andrews G, Charney DS, Sirovatka PJ, Regier DA (Hrsg) Stress-induced and fear circuitry disorders. Advancing the research agenda for DSM-V. American Psychiatric Association, Arlington, VA, S 195–214
Rapee RM, Schniering CA, Hudson JL (2009) Anxiety disorders during childhood and adolescence: origins and treatment. Annu Rev Clin Psychol 5:311–341
PubMedCrossRefRauch SL, Drevets WC (2009) Neuroimaging and neuroanatomy of stress-induced and fear circuitry disorders. In: Andrews G, Charney DS, Sirovatka PJ, Regier DA (Hrsg) Stress-induced and fear circuitry disorders. Advancing the research agenda for DSM-V. American Psychiatric Association, Arlington, VA, S 215–254
Rauch LS, Savage CR, Alpert NM et al (1995) A positron emission tomography study of simple phobic symptom provocation. Arch Gen Psychiatry 52:20–28
PubMedCrossRefReif A, Richter J, Straube B, Höfler M, Lueken U, Gloster AT, Weber H, Domschke K, Fehm L, Ströhle A, Jansen A, Gerlach A, Pyka M, Reinhardt I, Konrad C, Wittmann A, Pfleiderer B, Alpers GW, Pauli P, Lang T, Arolt V, Wittchen HU, Hamm A, Kircher T, Deckert J (2014) MOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. Mol Psychiatry 19(1):122–128
PubMedCrossRefRessler KJ, Rothbaum BO, Tannenbaum L et al (2004) Cognitive enhancers as adjuncts to psychotherapy: use of
d-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61:1136–1144
PubMedCrossRefRichter J, Hamm AO, Pané-Farré CA, Gerlach AL, Gloster AT, Wittchen HU, Lang T, Alpers GW, Helbig-Lang S, Deckert J, Fydrich T, Fehm L, Ströhle A, Kircher T, Arolt V (2012) Dynamics of defensive reactivity in patients with panic disorder and agoraphobia: implications for the etiology of panic disorder. Biol Psychiatry 72(6):512–520. doi:10.1016/j.biopsych.2012.03.035. Epub 22 May 2012
Rickels K (1978) Use of antianxiety agents in anxious outpatients. Psychopharmacology 58:1–17
PubMedCrossRefRickels K, Pollack MH, Sheehan DV et al (2000b) Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968–974
PubMedCrossRefRickels K, Zaninelli R, McCafferty J et al (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160:749–756
PubMedCrossRefRickels K, Mangano R, Khan A (2004) A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24:488–496
PubMedCrossRefRickels K, Pollack MH, Feltner DE et al (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:1022–1103
PubMedCrossRefRobichaud M, Dugas MJ (2009) Psychological treatment of generalized anxiety disorder. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 364–374
Rocah BS (1991) A clinical study of a phobic illness: the effects of traumatic scars on symptom formation and treatment. Psychoanal Inq 11:351–375
CrossRefRocca P, Fonzo V, Scotta M et al (1997) Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95:444–450
PubMedCrossRefRodebaugh TL, Holaway RM, Heimberg RG (2004) The treatment of social anxiety disorder. Clin Psychol Rev 24:883–908
PubMedCrossRefRodriguez BF, Weisberg RB, Pagano ME et al (2006) Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 194:91–97
PubMedPubMedCentralCrossRefRoelofs K, van Peer J, Berretty E et al (2009) Hypothalamus-pituitary-adrenal axis hyperresponsiveness is associated with increased social avoidance behaviour in social phobia. Biol Psychiatry 65:336–343
PubMedCrossRefRoemer L, Orsillo SM (2007) An open trial of an acceptance-based behavior therapy for generalized anxiety disorder. Behav Ther 38:72–85
PubMedCrossRefRollman BL, Belnap BH, Mazumdar S et al (2005) A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Arch Gen Psychiatry 62:1332–1342
PubMedCrossRefRoozendaal B, Okuda S, de Quervain DJ, McGaugh JL (2006) Glucocorticoids interact with emotion-induced noradrenergic activation in influencing different memory functions. Neuroscience 138:901–910
PubMedCrossRefRoozendaal B, McEwen BS, Chattarji S (2009) Stress, memory and the amygdale. Nat Rev Neurosci 10:423–433
PubMedCrossRefRosenthal M (2003) Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64:1245–1249
PubMedCrossRefRoss LE, McLean LM (2006) Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry 67:1285–1298
PubMedCrossRefRoth M (1960) The phobic anxiety-depersonalization syndrome and some general aetiological problems in psychiatry. J Neuropsychiatry 1:293–306
Roth A, Fonagy P (2005) What works for whom? A critical review of psychotherapy research, 2. Aufl. Guilford, New York/London
Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV (2012) Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol 22:858–866
PubMedCrossRefRoy-Byrne PP, Craske MG, Stein MB et al (2005) A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 62:290–298
PubMedPubMedCentralCrossRefRoy-Byrne P, Veitengruber JP, Bystritsky A et al (2009) Brief intervention for anxiety in primary care patients. J Am Board Fam Med 22:175–186
PubMedPubMedCentralCrossRefRudolf G, Grande T, Porsch U (1988) Die Berliner Psychotherapiestudie. Z Psychosom Med Psychoanal 34:2–18
PubMedRudolf G, Manz R, Öri C (1994) Ergebnisse psychoanalytischer Therapien. Z Psychosom Med Psychoanal 40:25–40
PubMedRuhmland M, Margraf J (2001) Effektivität psychologischer Therapien von spezifischer Phobie und Zwangsstörung: Meta-Analysen auf Störungsebene. Verhaltenstherapie 11:14–26
CrossRefRynn MA, Brawman-Mintzer O (2004) Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 9:716–723
PubMedCrossRefRynn M, Russell J, Erickson J et al (2008) Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible dose, progressive titration, placebo-controlled trial. Depress Anxiety 25:182–189
PubMedCrossRefSalzer S, Winkelbach C, Leweke F, Leibing E, Leichsenring F (2011) Long-term effects of short-term psychodynamic psychotherapy and cognitive-behavioural therapy in generalized anxiety disorder: 12-month follow-up. Can J Psychiatry 56(8):503–508
PubMedCrossRefSamochowiec J, Hajduk A, Samochowiec A et al (2004) Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. Psychiatry Res 128:21–26
PubMedCrossRefSánchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F, Gómez-Conesa A (2010) Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clin Psychol Rev 30:37–50
PubMedCrossRefSareen J, Cox BJ, Clara I, Asmundson GJ (2005) The relationship between anxiety disorders and physical disorders in the U.S. National Comorbidity Survey. Depress Anxiety 21(4):193–202
PubMedCrossRefSareen J, Chartier M, Paulus MP, Stein MB (2006) Illicit drug use and anxiety disorders: findings from two community surveys. Psychiatry Res 142:11–17
PubMedCrossRefSarlo M, Buodo G, Munafó M et al (2008) Cardiovascular dynamics in blood phobia: evidence for a key role of sympathetic activity in vulnerability to syncope. Psychophysiology 45:1038–1045
PubMedCrossRefSartorius N, Ustun TB, Lecrubier U et al (1996) Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry 168:38–43
CrossRefScheibe G, Tress W, Reister G (1997) Psychoanalytische Modellvorstellungen und die DSM-IV-Klassifikation von Angststörungen: Widerspruch oder Ergänzung? Z Psychosom Med Psychoanal 43:138–152
Schienle A, Schafer A, Walter B et al (2005) Brain activation of spider phobics towards disorder-relevant, generally disgust- and fear-inducing pictures. Neurosci Lett 388:1–6
PubMedCrossRefSchienle A, Schäfer A, Stark R, Vaitl D (2009) Long-term effects of cognitive behaviour therapy on brain activation in spider phobia. Psychiatry Res 172:99–102
PubMedCrossRefSchneier FR (2005) Neurobiological mechanisms of social anxiety disorder. CNS Spectr 10(Suppl 13):8–9
Schneier FR, Goetz D, Campeas R et al (1998) Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172:70–77
PubMedCrossRefSchneier FR, Liebowitz MR, Abi-Dargham A et al (2000) Low dopamine D2 receptor binding potential in social phobia. Am J Psychiatry 157:457–459
PubMedCrossRefSchneier FR, Abi-Dargham A, Martinez D et al (2009) Dopamine transporters, D2 receptors, and dopamine release in generalized social and anxiety disorder. Depress Anxiety 26:411–418
PubMedPubMedCentralCrossRefSchuebel K, Gitik M, Domschke K, Goldman D (2016) Making sense of epigenetics. Int J Neuropsychopharmacol 19:1–10
CrossRefSchulz J, Gotto JG, Rapaport MH (2005) The diagnosis and treatment of generalized anxiety disorder. Prim Psychiatry 12:58–67
Schuwald AM, Nöldner M, Wilmes T, Klugbauer N, Leuner K, Müller WE (2013) Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS One 8:e59998
PubMedPubMedCentralCrossRefScott KM, Wells JE, Angermeyer M et al (2009) Gender and the relationship between marital status and first onset of mood, anxiety and substance use disorders. Psychol Med 26:1–11
Seedat S, Scott KM, Angermeyer MC et al (2009) Cross-national associations between gender and mental disorders in World Health Organization World Mental Health Surveys. Arch Gen Psychiatry 66:785–795
PubMedPubMedCentralCrossRefSeligman MEP (1971) Phobias and preparedness. Behav Ther 2:307–320
CrossRefShear MK, Cooper AM, Klerman GL, Busch FN et al (1993) A psychodynamic model of panic disorder. Am J Psychiatry 150:859–866
PubMedCrossRefShear MK, Pilkonis PA, Cloitre M, Leon AC (1994) Cognitive behavioral treatment compared with nonprescriptive treatment of panic disorder. Arch Gen Psychiatry 51:395–401
PubMedCrossRefShear MK, Houck PM, Greeno C, Masters S (2001) Emotion-focused psychotherapy for patients with panic disorder. Am J Psychiatry 158:1993–1998
PubMedCrossRefShear K, Jin R, Ruscio AM, Walters EE, Kessler RC (2006) Prevalence and correlates of estimated DSM-IV child and adult separation anxiety disorder in the National Comorbidity Survey Replication. Am J Psychiatry 163:1074–1083
PubMedPubMedCentralCrossRefShiban Y, Pauli P, Mühlberger A (2013) Effect of multiple context exposure on renewal in spider phobia. Behav Res Ther 51(2):68–74
PubMedCrossRefShiban Y, Schelhorn I, Pauli P, Mühlberger A (2015) Effect of combined multiple contexts and multiple stimuli exposure in spider phobia: a randomized clinical trial in virtual reality. Behav Res Ther 71:45–53
PubMedCrossRefShin LM, Liberzon I (2010) The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 35:169–191
PubMedCrossRefShresta R, Natarajan N, Coplan JD (2009) Pathogeneis of panic disorder. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 381–398
Simon NM, Connor KM, LeBeau RT et al (2008) Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 197:675–681
CrossRefSimon NM, Kaufmann RE, Hoge EA et al (2009a) Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther 5:19–23
CrossRefSimon NM, Otto MW, Worthington JJ et al (2009b) Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry 70:1563–1570
PubMedPubMedCentralCrossRefSimpson HB, Schneider FR, Campeas R et al (1998) Imipramine in the treatment of social phobia. J Clin Psychopharmacol 18:132–135
PubMedCrossRefSinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A, Srivastava S, Nutt DJ, Davies SJ (2009) Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry 194(6):483–490
PubMedCrossRefSlaap BR, den Boer JA (2001) The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress Anxiety 14:112–122
PubMedCrossRefSlade T, Andrews G (2001) DSM-IV and ICD-10 generalized anxiety disorder: discrepant diagnoses and associated disability. Soc Psychiatry Psychiatr Epidemiol 36:45–51
PubMedCrossRefSmits JAJ, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, Pollack MH, Tart CD (2013)
d-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 73:1054–1058
PubMedPubMedCentralCrossRefSmoller JW, Simon NM, Pollack MH et al (1999) Anxiety in patients with pulmonary disease: comorbidity and treatment. Semin Clin Neuropsychiatry 4:84–97
PubMedSmoller JW, Yamaki LH, Fagerness JA et al (2005) The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry 57:1485–1492
PubMedCrossRefSmoller JD, Gardner-Schuster E, Covino J (2008) The genetics basis of panic and phobic anxiety disorders. Am J Med Genet Part C Semin Med Genet 148C:118–126
PubMedCrossRefSomers JM, Goldner EM, Waraich P, Hsu L (2006) Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 51:100–113
PubMedCrossRefSoravia LM, Heinrichs M, Aerni A et al (2006) Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A 103:5585–5590
PubMedPubMedCentralCrossRefSpielberger CD (Hrsg) (1966) Anxiety and behavior. Academic, New York
Spielberger CD, Gorsuch RL, Lushene RE (1970) State-trait anxiety inventory („self-evaluation questionnaire“). Consulting Psychologists Press, Palo Alto
Starcevic V (2008) Treatment of panic disorder: recent developments and current status. Expert Rev Neurother 8:1219–1232
PubMedCrossRefStarcevic V, Berle D (2006) Cognitive specificity of anxiety disorders: a review of selected key constructs. Depress Anxiety 23:51–61
PubMedCrossRefSteel Z et al (2014) The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol 43:476–493
PubMedPubMedCentralCrossRefStein DJ, Matsunaga H (2006) Specific phobia: a disorder of fear conditioning and extinction. CNS Spectr 11:248–251
PubMedCrossRefStein MG, Stein DJ (2008) Social anxiety disorder. Lancet 371:1115–1125
PubMedCrossRefStein MB, Uhde TW (1998) Biology of anxiety disorders. In: Schatzberg AF, Nemeroff CB (Hrsg) Textbook of psychopharmacology, 2. Aufl. American Psychiatric Press, Washington, DC, S 609–628
Stein DJ, Berk M, Els C et al (1999) A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J 89:402–406
PubMedStein DJ, Cameron A, Amrein R, Moclobemide Social Phobia Clinical Study Group et al (2002a) Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 17:161–170
PubMedCrossRefStein DJ, Versiani M, Hair T et al (2002b) Efficacy of paroxetine for relapse prevention on social anxeity disorder: a 24-week study. Arch Gen Psychiatry 59:1111–1118
PubMedCrossRefStein MB, Goldin PR, Sareen J et al (2002c) Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 59:1027–1034
PubMedCrossRefStein DJ, Westenberg HG, Yang H et al (2003) Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 6:317–323
PubMedCrossRefStein MB, Pollack MH, Bystrritsky A et al (2005) Efficacy of low and higher dose extended – release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177:280–288
CrossRefStein MB, Seedat S, Gelernter J (2006) Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 187:68–72
CrossRefStein DJ, Ahokas AA, de Bodinat C (2008a) Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo controlled study. J Clin Psychopharmacol 28:561–566
PubMedCrossRefStein DJ, Baldwin DS, Baldinetti F, Mandel F (2008b) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 18:422–430
PubMedCrossRefStein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H (2011) Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol 26:614–628
PubMedCrossRefStein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C (2012) Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 73:1002–1008
PubMedCrossRefStein DJ, Ahokas A, Márquez MS, Höschl C, Oh KS, Jarema M, Avedisova AS, Albarran C, Olivier V (2014) Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry 75:362–368
PubMedCrossRefStinson FS, Dawson DA, Chou PS et al (2007) The epidemiology of DSM-IV specific phobia in the USA: results form the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 37:1047–1059
PubMedCrossRefStocchi F, Nordera G, Jokinen RH et al (2003) Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250–258
PubMedCrossRefStraube T, Mentzel HJ, Glauer M, Miltner WH (2004) Brain activation to phobia-related words in phobic subjects. Neurosci Lett 372:204–208
PubMedCrossRefStraube T, Glauer M, Dilger S et al (2006a) Effects of cognitive-behavioral therapy on brain activation in specific phobia. Neuroimage 29:125–135
PubMedCrossRefStraube T, Mentzel HJ, Miltner WH (2006b) Neural mechanisms of automatic and direct processing of phobogenic stimuli in specific phobia. Biol Psychiatry 59:162–170
PubMedCrossRefStraube B, Reif A, Richter J, Lueken U, Weber H, Arolt V, Jansen A, Zwanzger P, Domschke K, Pauli P, Konrad C, Gerlach AL, Lang T, Fydrich T, Alpers GW, Ströhle A, Wittmann A, Pfleiderer B, Wittchen HU, Hamm A, Deckert J, Kircher T (2014) The functional -1019C/G HTR1A polymorphism and mechanisms of fear. Transl Psychiatry 4:e490
PubMedPubMedCentralCrossRefStrauss B, Burgmeier-Lohse M (1994) Evaluation einer stationären Langzeitgruppenpsychotherapie. Ein Beitrag zur differentiellen Psychotherapieforschung im stationären Feld. Psychother Psychosom Med Psychol 44:184–192
PubMedStravynski A, Arbel N, Bounader J et al (2000) Social phobia treated as a problem in social functioning: a controlled comparison of two behavioural group approaches. Acta Psychiatr Scand 102:188–198
PubMedCrossRefStröhle A, Kellner M, Yassouridis A et al (1998) The effects of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 155:610–612
PubMedCrossRefSuárez LM, Bennett SM, Goldstein CR, Barlow DH (2009) Understanding anxiety disorders from a „tripple vulnerability“ framework. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 153–172
Susman J, Klee B (2005) The role of high-potency benzodiazepines in the treatment of panic disorder. Prim Care Companion J Clin Psychiatry 7:5–11
PubMedPubMedCentralCrossRefTancer ME, Stein MB, Uhde TW (1993) Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 34:591–595
PubMedCrossRefTaylor J (1953) A personality scale of manifest anxiety. J Abnorm Soc Psychol 48:285–290
CrossRefTaylor S (1996) Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry 27:1–9
PubMedCrossRefThase ME, Jindal RD (2004) Combining psychotherapy and psychopharmacology for treatment of mental disorders. In: Lambert MJ (Hrsg) Bergin and Garfield’s handbook of psychotherapy and behaviour change, 5. Aufl. Wiley, New York, S 743–766
Thoeringer CK, Binder EB, Salyakina D et al (2007) Association of a Met88Val diazepam binding inhibitor (DBI) gene polymorphism and anxiety disorders with panic attacks. J Psychiatr Res 41:579–584
PubMedCrossRefTiihonen J, Kuikka J, Bergstrom K et al (1997a) Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 154:239–242
PubMedCrossRefTiihonen J, Kuikka J, Rasanen P et al (1997b) Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry 2:463–471
PubMedCrossRefTillfors M, Furmark T, Marteinsdottir I et al (2001) Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am J Psychiatry 158:1220–1226
PubMedCrossRefTillfors M, Furmark T, Marteinsdottir I, Fredrikson M (2002) Cerebral blood flow during anticipation of public speaking in social phobia: a PET study. Biol Psychiatry 52:1113–1119
PubMedCrossRefTolin DF, Gilliam CM, Dufresne D (2009) The economic and social burden of anxiety disorders. In: Stein DJ, Hollander, Rothbaum BO (Hrsg) Textbook of anxiety disorders. American Psychiatric Publishing, Washington, DC/London, S 731–746
Torgersen S (1979) The nature and origin of common phobic fears. Br J Psychiatry 40:1085–1089
Trower P, Gilbert P (1989) New theoretical conceptions of social anxiety and social phobia. Clin Psychol Rev 9:19–35
CrossRefTrull TJ, Nietzel MT, Maier A (1988) The use of meta-analysis to assess the clinical significance of behavior therapy for agoraphobia. Behav Ther 19:527–538
CrossRefTyrer P (1992) Anxiolytics not acting at the benzodiazepine receptor: beta blockers. Prog Neuropsychopharmacol Biol Psychiatry 16:17–26
PubMedCrossRefTyrer P, Seivewright H, Johnson D (2004) The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med 34:1385–1394
PubMedCrossRefUlrich-Lai YM, Herman JP (2009) Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 10:397–409
PubMedPubMedCentralCrossRefVan Ameringen M, Mancini C, Szechtman H et al (2004) A PET provocation study of generalized social phobia. Psychiatry Res 132:13–18
PubMedCrossRefVan Ameringen M, Mancini C, Patterson B (2009) Pharmacotherapy for social anxiety disorder and specific phobia. In: Anthony MM, Stein MB (Hrsg) Oxford handbook of anxiety and related disorders. Oxford library of psychology. Oxford University Press, Oxford, S 321–333
Van Balkom AJ, Bakker A, Spinhoven P et al (1997) A meta-analysis of the treatment of panic disorder with and without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 185:510–516
PubMedCrossRefVan Balkom AJ, van Boeijen CA, Boeke AJ et al (2008) Comorbid depression, but not comorbid anxiety disorders, predicts poor outcome in anxiety disorders. Depress Anxiety 25:405–415
Van der Linden G, van der Heerden B, Warwick J et al (2000) Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuropsychopharmacol Biol Psychiatry 24:419–438
PubMedCrossRefVan der Wee NJ, van Veen JF, Stevens H et al (2008) Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 1231-beta-(4-iodophenyl)-tropane SPECT. J Nucl Med 49:757–763
PubMedCrossRefVan Vliet IM, den Boer JA, Westenberg HG (1992) Psychopharmacological treatment of social phobia: clinical and biochemical aspects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 2:21–29
PubMedCrossRefvan Vliet IM, den Boer JA, Westenberg HG, Pian KL (1997) Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 58(4):164–8
PubMedCrossRefVanelli M (2005) Improving treatment response in panic disorder. Prim Psychiatry 12:68–73
Venturello S, Barzega G, Maina G, Bogetto F (2002) Premorbid conditions and precipitating events in early-onset panic disorder. Compr Psychiatry 43:28–36
PubMedCrossRefVerburg C, Griez E, Meijer J (1994) A 35 carbon dioxide challenge in simple phobias. Acta Psychiatr Scand 90:420–423
PubMedCrossRefVerburg K, Griez E, Meijer J, Pols H (1995) Respiratory disorders as a possible predisposing factor for panic disorder. J Affect Disord 33:129–134
PubMedCrossRefVersiani M, Nardi AE, Mundim FD et al (1992) Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353–360
PubMedCrossRefVersiani M, Nardi AE, Figueria J et al (1997) Double-blind placebo-controlled trial with bromazepam in social phobia. J Bras Psiquiatr 46:167–171
Vickers K, McNallly RJ (2004) Is premenstrual dysphoria a variant of panic disorder? A review. Clin Psychol Rev 24:933–956
PubMedVriends N, Becker ES, Meyer A et al (2007a) Subtypes of social phobia: are they of any use. J Anxiety Disord 21:320–337
PubMedCrossRefVriends N, Becker ES, Meyer A et al (2007b) Recovery from social phobia in the community and its predictors: data from a longitudinal epidemiological study. J Anxiety Disord 21:59–75
PubMedCrossRefVythilingum B (2008) Anxiety disorders in pregnancy. Curr Psychiatry Rep 10:331–335
PubMedCrossRefWagner R, Silove D, Marnane C, Rouen D (2006) Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J Anxiety Disord 20:363–371
PubMedCrossRefWalker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, Johnston DC, Lavallie YJ, Nandy S, Pecknold JC, Hadrava V, Lane RM (2000) Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20(6):636–44
PubMedCrossRefWalker DL, Toufexis DJ, Davis M (2003) Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 463:199–216
PubMedCrossRefWatanabe N, Churchill R, Furukawa TA (2009) Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database Syst Rev CD005335
Watson D (2009) Differentiating the mood and anxiety disorders: a quadripartite model. Annu Rev Clin Psychol 5:221–247
PubMedCrossRefWeisberg RB (2009) Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry 2:4–9
CrossRefWeissman MM, Fyer AJ, Haghighi F et al (2000) Potential panic disorder syndrome: clinical and genetic linkage evidence. Am J Med Genet 96:24–35
PubMedCrossRefWells A (2006) Metacognitive therapy for worry and generalized anxiety disorder. In: Davey GCL, Wells A (Hrsg) Worry in its psychological disorders: theory, assessment and treatment. Wiley, Chichester, S 259–272
Wells A, King P (2006) Metacognitive therapy for generalized anxiety disorder: an open trial. J Behav Ther Exp Psychiatry 37:206–212
PubMedCrossRefWells A, Papageorgiou C (2001) Brief cognitive therapy for social phobia: a case series. Behav Res Ther 39:713–720
PubMedCrossRefWesten D, Morrison K (2001) A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol 69:875–899
PubMedCrossRefWestenberg HGM (2009) Recent advances in understanding and treating social anxiety disorder. CNS Spectr 14(Suppl 3):24–33
PubMedCrossRefWestphal C (1871) Die Agoraphobie, eine neuropathische Erscheinung. Arch Psychiatr Nervenkr 3:138–161
CrossRefWetherell JL, Afari N, Ayers CR, Stoddard JA, Ruberg J, Sorrell JT, Liu L, Petkus AJ, Thorp SR, Kraft A, Patterson TL (2011) Acceptance and Commitment Therapy for generalized anxiety disorder in older adults: a preliminary report. Behav Ther 42(1):127–134
PubMedCrossRefWhalen PJ, Shin LM, McInerney SC et al (2001) A functional MRI study of human amygdala responses to facial expressions of fear versus anger. Emotion 1:70–83
PubMedCrossRefWhalen PJ, Honstone T, Somerville LH et al (2008) A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry 63:858–863
PubMedCrossRefWhiting PJ (2003) GABAA receptor subtypes in the brain: a paradigm of CNS drug discovery. Drug Discov Today 8:445–450
PubMedCrossRefWiborg IM, Dahl AA (1996) Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Arch Gen Psychiatry 53:689–694
PubMedCrossRefWise MG, Rundell JR (2005) Clinical manual of psychosomatic medicine. A guide to consultation-liaison psychiatry. American Psychiatric Publishing, Washington, DC/London
Wittchen HU, Jacobi F (2005) Size and burden of mental disorder in Europe: a critical review and appraisal for 27 studies. Eur Neuropsychopharmacol 15:357–376
PubMedCrossRefWittchen HU, Zhao S, Kessler RC, Eaton WW (1994) DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51(5):355–64
PubMedCrossRefWittchen HU, Reed V, Kessler RC (1998) The relationship of agoraphobia and panic in a community sample of adolescents and young adults. Arch Gen Psychiatry 55:1017–1024
PubMedCrossRefWittchen HU, Kessler RC, Beesdo K et al (2002) Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 8:24–34
Wittchen HU, Nocon A, Beesdo K et al (2008) Agoraphobia and panic. Prospective-longitudinal relations suggest a rethinking of diagnostic concepts. Psychother Psychosom 77:147–157
PubMedCrossRefWittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655–79
PubMedCrossRefWolitzky-Taylor KB, Horowitz JD, Powers MB et al (2008) Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev 28:1021–1037
PubMedCrossRefWolpe J (1958) Psychotherapy by reciprocal inhibition. Stanford University Press, Stanford
Wolpe J, Lang PJ (1964) A fear survey for use in behaviour therapy. Behav Res Ther 2:27–30
PubMedCrossRefYerkes RM, Dodson JD (1908) The relation of strength of stimulus to rapidity of habit-formation. J Comp Neurol Psychol 18:459–482
CrossRefYonkers KA, Warshaw MG, Massion AO (1996) Phenomenology and course of generalized anxiety disorder. Br J Psychiatry 168:308–313
PubMedCrossRefYonkers KA, Dyck IR, Keller MB (2001) An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women. Psychiatr Serv 52:637–643
PubMedCrossRefYonkers KA, Bruce SE, Dyck IR, Keller MB (2003) Chronicity, relapse, and illness – course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety 17:173–179
PubMedCrossRefYou JS, Hu SY, Chen B, Zhang HG (2005) Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Genet 15:7–11
PubMedCrossRefZerbe KJ (1994) Uncharted waters: psychodynamic considerations in the diagnosis and treatment of social phobia. Bull Menninger Clin 58(Suppl A):A3–A20
PubMedZerbe KJ (1997) Uncharted waters: psychodynamic considerations in the diagnosis and treatment of social phobia. In: Menninger WW (Hrsg) Fear of humiliation: integrated treatment of social phobia and comorbid conditions. Jason Aronson, Northvale, S 1–19
Zhang W, Connor KM, Davidson JR (2005) Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 19(5):551–3
PubMedCrossRefZiegler C, Dannlowski U, Bräuer D, Stevens S, Laeger I, Wittmann H, Kugel H, Dobel C, Hurlemann R, Reif A, Lesch KP, Heindel W, Kirschbaum C, Arolt V, Gerlach AL, Hoyer J, Deckert J, Zwanzger P, Domschke K (2015) Oxytocin receptor gene methylation: converging multilevel evidence for a role in social anxiety. Neuropsychopharmacology 40(6):1528–1538
PubMedPubMedCentralCrossRefZiemann AE, Allen JE, Dahdaleh NS, Drebot II, Coryell MW, Wunsch AM, Lynch CM, Faraci FM, Howard MA 3rd, Welsh MJ, Wemmie JA (2009) The amygdala is a chemosensor that detects carbon dioxide and acidosis to elicit fear behavior. Cell 139(5):1012–1021
PubMedPubMedCentralCrossRefZimmerman M, Rothschild L, Chelminski I (2005) The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry 162:1911–1918
PubMedCrossRefZinbarg RE, Craske MG, Barlow DH (2006) Mastery of your anxiety and worry (therapist guide), 2. Aufl. Oxford University Press, New York/Oxford
CrossRefZung WWK (1971) A rating scale for the anxiety disorders. Psychosomatics 12:371–379